Impact of MRD before and after allogeneic hematopoietic cell transplantation (HCT) of childhood ALL by FC and RQ-PCR: a retrospective study on behalf of COG, the PBMTC, the I-BFM, the PDWP of the EBMT and the Westhafen-intercontinental-group : O001
Previously published : O002
The UM171 cord blood expansion trial: smaller, better HLA matched cords in short 7 day fedbatch cultures already provide clinical and cost benefits : O003
Letermovir (LET) for prevention of cytomegalovirus (CMV) infection: results from a phase III randomized, double-blind, placebo (PBO)-controlled trial in adult allogeneic hematopoietic cell transplant (alloHCT) recipients : O004
Previously published : O005
Application of the disease risk index for risk stratification of allogeneic hematopoietic stem cell transplantation in a large cohort of the European Society for Blood and Marrow Transplantation (EBMT) : O006
Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study : O007
Inotuzumab ozogamicin (InO) versus standard of care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase 3 INOVATE trial: outcomes in patients who received post-study hematopoietic stem cell transplantation (HSCT) : O008
Previously published : O009
Allogeneic hematopoietic stem cell transplantation outcomes after nivolumab monotherapy for +relapsed/refractory hodgkin lymphoma (CheckMate 039 and CheckMate 205) : O010
A phase III, double-blind, randomized, placebo-controlled, multicenter clinical trial to study the safety, tolerability, efficacy, and immunogenicity of inactivated VZV vaccine (ZVIN) in recipients of autologous hematopoietic stem cell transplants (auto-HSCT) : O011
High exposure to fludarabine in conditioning prior to allogeneic hematopoietic cell transplantation predicts for impaired CD4 reconstitution and lower survival chances : O012
Previously published : O013
Impact of G-CSF mobilization on T-cell functionality: New aspects for adoptive immunotherapy : O014
Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis : O015
The value of post thaw CD34 count with and without DMSO removal in the setting of autologous stem cell transplantation : O016
Safety and efficacy trial of escalation of plerixafor for mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) and evaluation of globin gene transfer in patients with sickle cell disease. preliminary results : O017
Engraftment of donor cells after allogeneic stem cell transplantation: comparison and impact of chimerism in whole blood and peripheral CD3+ T-cells : O018
Pegivirus in hematopoietic stem cell transplant recipients: a longitudinal prevalence study and association with immune reconstitution and clinical outcomes : O019
Meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis : O020
Molecular demonstration of a pneumocystis outbreak in stem cell transplant patients: evidence for transmission in the daycare center : O021
Previously published : O022
Outcome of allogeneic hematopoietic stem cell transplantation in children and adults with prior invasive fungal diseases : O023
Gram-negative bacteremia in children after allogeneic hematopoietic stem cell transplantation (HSCT): a multinational study on behalf of Infectious Diseases Working Party of European Society for Blood and Marrow Transplant (EBMT-IDWP) : O024
Quantitative PCR in fresh gastrointestinal mucosa is faster, more objective, and more reliable than immunohistochemistry for the diagnosis of CMV gastrointestinal disease : O025
Proven and probable lower respiratory tract viral infection in acute leukemia patients and after hematopoietic cell transplantation predicts outcome : O026
Drug resistant lymphocyte immunotherapy: Dose and schedule optimization : O027
CD19-specific CAR T cells with a central memory and stem memory phenotype-automated generation in a closed, gmp-compatible system from peripheral blood of pediatric patients with acute lymphoblastic leukemia : O028
Checkpoint blockade with pembrolizumab induce graft-versus-host disease for patients with refractory acute leukemia heavily treated after allogeneic transplantation : O029
Vaccines are safe and effective after T-cell depleted CD34-selected allogeneic hematopoietic stem cell transplantation (Allo HCT) : O030
Nivolumab salvage therapy before and after allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma : O031
Previously published : O032
S1P modulator FTY720 regulates osteoclast precursor mobilization and targets osteoclastogenesis in multiple myeloma systemic xenograft model : O033
Decitabine enhances targeting of acute myeloid leukemia cells by umbilical cord blood CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice : O034
Allogeneic bone marrow transplantation (BMT) without ATG versus allogeneic peripheral blood stem cell transplantation (PBSCT) with ATG in AML patients given grafts from HLA-identical siblings: a retrospective study by the ALWP of the EBMT : O035
Previously published : O036
Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission : O037
Cost-effectiveness analysis of haploidentical versus matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years : O038
Role of graft cell composition and source in haploidentical transplantation using post-transplant cyclophosphamide : O039
Human memory B cells reside in the bone marrow and are equipped with an α-defensin weapon-the bone marrow as a source for immunocompetent memory cells for transplantation : O040
Previously published : O041
Outcome of children with acute leukemia given allogeneic HSCT either from an unrelated donor (UD-HSCT) or from an HLA-partially matched relative after αβ-T cell/B-cell depletion (αβhaplo-HSCT) : O042
Anti GvHD prophylaxis shape the effect of HLA mismatches on the unshared haplotype in T-cell repleted haploidentical stem cell transplantation: a study from the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation (EBMT) : O043
Previously published : O044
Outcomes after matched unrelated donor and non-T-cell depleted haploidentical stem cell transplantation in patients ≥60 years with acute myeloid leukemia: A comparative study on behalf of the ALWP of the EBMT : O045
Lower incidence of GVHD after haploidentical compared to unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single center experience of 225 patients : O046
The older stem cell donor in the Netherlands—a survey on medical assessment, comorbidity and outcome : O047
KIR-ligand mismatching is associated with inferior survival in patients with acute leukemia following T-cell replete haplo-identical transplantation with post-transplant cyclophosphamide. a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) : O048
Comparison of matched- unrelated donors versus alternative donor (9/10) unrelated donor, cord blob unit and haplo-identical donor) in allogeneic stem cell transplantation (allo-SCT) for acute lymphoblastic leukemia (ALL) in CR2: a report of 841 patients from the EBMT Acute Leukemia Working Party : O049
Bendamustine-Based (BeEAM) conditioning before autologous stem cell transplantation: results of a multicenter study of 474 patients : O050
Outcome of autologous non-myeloablative hematopoietic stem cell transplantation in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP) : O051
Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC) : O052
Screening for NY-ESO-1 expression as a cancer immunotherapy target in soft-tissue sarcoma : O053
Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune diseases, inborn errors and paediatric working parties : O054
Previously Published : O055
Extended analysis of HLA-G polymorphisms and outcome in metastatic renal cell carcinoma patients undergoing allografting : O056
Previously Published : O057
Autologous stem cell transplantation (ASCT) in relapse remitting (RR-MS) and secondary progressive multiple sclerosis (SP-MS): an Australian-based prospective phase II trial : O058
Impact of HLA disparity on GvHD and relapse rate in haploidentical transplants followed by high dose post-transplant cyclophosphamide : O059
IL-22+γδT17 as the core of cellular crosstalk networks in intestinal acute graft-versus-host disease : O060
Oral Syk inhibitor, Entospletinib (GS-9973), controls disease and enhances survival in a mouse model of chronic graft-versus host disease (cGVHD) : O061
Previously published : O062
Safety and efficacy of placenta derived decidua stroma cells in experimental studies and in clinical settings : O063
Metabolic serum profiles and chronic graft versus host disease among patients receiving allogeneic stem cell transplantation : O064
Lymphangiogenesis as therapeutic target during acute GVHD : O065
Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation : O066
Significant association of IgG glycan structures with intensity of immunosuppression among chronic graft-versus-host disease patients: results of the NIH cohort study : O067
Previously published : O068
Chronic graft-versus-host-disease and B-cell reconstitution after hematopoietic stem cell transplantation in children : O069
Extended MHC haplotype disparity level is more relevant then the level of HLA mismatch alone for the patients survival and graft versus host disease in T cell-replate HSCT from unrelated donor : O070
Reg3 alpha serum levels in the course of allogeneic SCT — Synergistic impact of dysbiosis and mucosal damage : O071
Recipient rs17281995 (CD86) and rs2069727 (IFNg) single nucleotide polymorphisms are associated with a lower risk of graft versus host disease in patients receiving an allogeneic stem-cell transplant from a related donor after a reduced intensity conditioning regimen: A multicenter experience : O072
Impact of graft-versus-host disease on outcomes after pediatric single cord blood transplantation: a retrospective analysis from the JSHCT GVHD Working Group : O073
Interleukin-6 is an early biomarker for acute GvHD and survival after allogeneic transplant : O074
Nervous system regulates thymic regeneration after immune injuries : O075
Prospective multicenter pilot phase II Study of sequential infusion of donor lymphocyte infusion (DLI) and Cytokine Induced Killer (CIK) cells for patients with relapse after allogeneic transplantation : O076
Rapid process for the generation of functional chimeric antigen receptors against novel targets : O077
The infusion of multi-antigen specific T-cell products for the prevention of viral infections after T-cell depleted allogeneic stem cell transplantation : O078
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study : O079
Five years of therapy with donor and 3rd party derived EBV and CMV specific cytotoxic T cells - safety after more than 1,000 infusions : O080
Treatment of post-allogeneic stem cell transplant cytopenias with sequential doses of mesenchymal stromal cells: results of a multicenter Phase II trial : O081
Adoptive transfer of CMV-specific T cells for persistent CMV infection after haploidentical stem cell transplantation: association between antiviral immunity and the improving of quantity and quality of CMV-specific T cells : O082
Efficacy and safety of defibrotide in patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) onset diagnosed after day 21: a post hoc interim subgroup analysis from an Expanded-Access Program : O083
Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation : O084
Microbiome-derived markers predict the clinical outcome of allogeneic hematopoietic stem cell transplant recipients: results of a prospective study in 100 adult patients : O085
Outcome of second cancer after hematopoietic stem cell transplantation: On behalf of the complications and quality of life working party of the EBMT : O086
Final efficacy and safety results from a defibrotide expanded-access program for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome : O087
Prevalence and predictors of cardiovascular risk in patients with moderate and severe chronic graft-versus-host disese : O088
Performance status drives the impact of age on the outcomes of autologous hematopoietic cell transplantation in elderly patients aged 65 and older: A retrospective analysis by the complications and quality of life working party of the EBMT : O089
Early cardiotoxicity associated with post-transplant cyclophosphamide in haploidentical stem cell transplantation : O090
Impact of extramedullary disease in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT : O091
Previously published : O092
Outcome of the rare myeloma subtypes: An analysis of the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) data : O093
WT1 heteroclitic epitope immunization following autologous stem cell transplantation induces WT1-specific immune responses and improves survival in patients with high-risk multiple myeloma : O094
Long follow-up of upfront tandem auto-allo transplant in multiple myeloma and impact of “new drugs” at relapse : O095
Previously published : O096
Comprehensive analysis of 212 donor lymphoycte infusions after allograft in multiple myeloma provides evidence for a strong graft versus myeloma (GvM) effect : O097
Achievement of stringent CR at day 100 after allogeneic SCT as salvage therapy for first relapse after autografting in multiple myeloma patients is associated with improved survival outcomes : O098
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine as conditioning regimen for matched sibling and unrelated donor transplant in patients with acute myeloid leukemia in fist complete remission. A study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT) : O099
Outcomes after single cord blood and unmanipulated haploidentical stem cell transplantation using thiotepa-busulfan-fludarabine (TBF) as myeloablative conditioning in adult patients with acute myeloid leukemia in complete remission: a comparative study on behalf of EUROCORD and the ALWP of the EBMT : O100
Previously Published : O101
The outcome of BEAC conditioning regimen prior to autologous stem cell transplant in non-Hodgkin lymphoma (NHL) and comparison with BEAM conditioning: a Lymphoma Working Party-EBMT study : O102
Previously Published : O103
Melphalan 140mg/m2 demonstrates identical clinical outcomes to melphalan 200mg/m2 amongst patients undergoing autologous transplant for multiple myeloma: a multicentre UK study : O104
Sequential conditioning with Thiotepa in T-cell replete HLA-haploidentical hematopoietic stem cell transplantation for the treatment of refractory hematological malignancies: comparison with matched related and unrelated donors : O105
Previously Published : O106
A Rapid and Sensitive molecular tool for the early diagnosis of hla loss relapses after partially-incompatible allogeneic HSCT : O107
Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT- Cellular Therapy & Immunobiology Working Party : O108
Multiple inhibitory receptors are expressed on central memory and memory stem T cells infiltrating the bone marrow of AML patients relapsing after allo-HSCT : O109
Dynamics of expression of Programmed cell death protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation : O110
Relapse of myeloid malignancies after allogeneic stem cell transplantation-a single center analysis : O111
Unmanipulated haploidentical donor transplantation is superior to matched sibling donor transplantation in eradicating pre-transplantation minimal residual disease as determined by multiparameter flow cytometry : O112
Molecular monitoring of acute myeloid leukemia using targeted ultra-deep sequencing : O113
Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4+ T-cell reconstitution : O114
Previously Published : O115
Umbilical cord blood transplantation versus unrelated donor transplantation in adults with relapsed or primary refractory acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the EBMT : O116
The value of allogeneic stem cell transplantation in patients with intermediate risk (ELN) acute myeloid leukemia with no FLT3-ITD, no NPM1 mutations and no CEBPA double mutations : O117
Previously Published : O118
Previously Published : O119
Previously Published : O120
Post transplant cyclophosphamide (PT-Cy) in association to standard GVHD prophylaxis in sibling and unrelated allogeneic stem cell transplantation (HSCT) for patients with acute leukemia, a survey from the ALWP of EBMT : O121
Second allograft for relapsed or refractory acute myeloid leukemia after first allogeneic stem cell transplantation: a study on behalf of the SFGM-TC : O122
Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses : O123
Regional intra-arterial steroids for steroid resistant/dependent GVHD is associated with lower tendency of viral reactivation and disease : O124
Donor Interleukin-7 receptor α-chain genotype predicts chronic GVHD after allogeneic HSCT : O125
Third party fecal microbiota transplantation (FMT) in hematopoietic cell transplantation (HCT) recipients : O126
What is the outcome in patients with acute leukemia who survive svere acute graft-versus-host disease? : O127
Previously Published : O128
Previously Published : O129
Post-transplant cyclophosphamide-based HLA 7/8 mismatched allogeneic transplantation is associated with lower incidence of chronic GVHD and similar survival outcomes in comparison with conventional HLA 8/8 unrelated transplantation : O130
Infectious complications in multiple myeloma patients after high dose chemotherapy and autologous stem cell transplantation-multicenter analysis of the Polish Adult Leukemia Group PALG : O131
Epstein-Barr virus-related disease after allogeneic HSCT and use of pre-emptive rituximab: clinical features and outcome : O132
Immunomodulatory role of polymyxin B hemoperfusion in gram negative sepsis following stem cell transplant : O133
Interferon-gamma production-based virus specific T cell detection by functional flow cytometry after allogeneic haematopoietic stem cell transplantation : O134
Risk factors for HPV positivity in Patients who received allogeneic stem cell transplants : O135
Safety and outcome of brincidofovir/(CMX001) in patients with adenoviraemia: a single-centre experience : O136
Interdisciplinary german survey about BK polyomavirus associated haemorrhagic cystitis in adult allogeneic stem cell transplantation : O137
Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the francophone society of stem cell transplantation and cellular therapy (SFGM-TC) study : O138
Better outcome with haploidentical donors compared to HLA-matched sibling donors after allogeneic hematopoietic cell transplantation for Hodgkin's lymphoma: a retrospective study from the SFGM-TC : O139
Long-term follow-up of patients undergoing reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma. a study of the Lymphoma Working Party-EBMT : O140
Previously Published : O141
Salvage Brentuximab Vedotin prior to allogeneic hematopoietic cell transplantation in classical Hodgkin lymphoma does not impact survival but reduces the incidence of chronic GVHD: a retrospective study of the EBMT Lymphoma Working Party : O142
Prospective phase 2 trial of high-dose gemcitabine/busulfan/melphalan (Gem/Bu/Mel) with autologous stem-cell transplant in poor risk relapsed or refractory hodgkin's lymphoma: a comparison with a concurrent matched cohort treated with beam : O143
Long-term impact of up-front ASCT combined with Rituximab in Non Hodgkin Lymphoma (NHL): an analysis of toxicity and fatigue in Lymphoma Study Association (LYSA) trials, the SIMONAL study : O144
Haploidentical transplantation for Hodgkin lymphoma relapsed after autologous transplant: reduced incidence of relapse and of chronic GVHD compared to HLA-identical related donors : O145
Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial : O146
Haplo-identical transplantation (haplo-HSCT) in patients with myelodysplastic syndrome (MDS): a report from the European Society of Blood and Marrow Transplantation : O147
Long-term survival of patients with MDS after allogeneic transplantation: a report from the Chronic Malignancies Working Party of EBMT : O148
Fludarabine/treosulfan is a promising condition for MDS/CMML-patients: a retrospective single center study : O149
Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) : O150
Bridging with Idelalisib appears safe in patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic stem cell transplantation (alloHCT): A Report from the EBMT Chronic Malignancies Working Party : O151
Previously Published : O152
Previously Published : O153
Previously Published : O154
Previously Published : O155
Maribavir versus valganciclovir for pre-emptive treatment of cytomegalovirus viraemia: a randomized, dose-ranging, phase 2 study among haematopoietic stem cell transplant and solid organ transplant recipients : O156
Establishing a standardized system to capture chronic graft-versus-host disease (GVHD) data in accordance to the national institutes (NIH) consensus criteria : O157
Optimizing anti-thymocyte globulin exposure to improve survival chances after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome : O158
Upfront alternate donor HSCT for children with severe aplastic anemia: a single center prospective clinical trail outcome : O159
EWOG-MDS study SCT RC RIC 06: Reduced intensity conditioning for children and adolescents with refractory cytopenia of childhood : O160
Second allogeneic stem cell transplantation for children and adolescents following relapse after first transplantation for MDS with excess of blasts-a study of the European Working Group of MDS in childhood (EWOG-MDS) : O161
Outcomes of hematopoietic stem cell transplantation for acute lymphoblastic leukemia: a comparative study between adolescents-young adults and children. A study on behalf of the SFGM-TC : O162
Previously Published : O163
Haematopoietic cell transplant (HCT) in pediatric acute myeloid leukemia (AML) after similar upfront therapy with AML-nopho; a comparison of conditioning regimens : O164
Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients : O165
Solid organ transplantation (SOT) after haematopoietic stem cell transplantation (HSCT) in pediatric patients. a multicentric retrospective EBMT study; on behalf of Paediatric Disease Working Party (PDWP) : O166
Previously Published : O167
Haematopoietic stem cell transplant in children with cytidine triphosphate synthase 1 (CTPS1) mutation : O168
Treatment of LPS-Responsive Beige-Like Anchor Protein (LRBA) deficiency by allogeneic hematopoietic stem cell transplantation: A joint IEWP-EBMT-ESID-PIDTC study : O169
Update on safety and efficacy of lentiviral hematopoietic stem cell gene therapy (HSC-GT) for metachromatic leukodystrophy (MLD) : O170
Fertility in long-term survivors of HSCT for primary immune deficiency: a preliminary study : O171
Outcome of allogeneic hematopoietic stem cell transplantation (allo HCT) in erythropoietic porphyria (EP) — on behalf of EBMT-IEWP : O172
Single Centre Retrospective Analysis of 6 Patients with Autosomal Recessive IFN-gamma-Receptor Deficiency : O173
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors : O174
Perceptions of caregivers and healthcare providers about therapies after pediatric allogeneic stem cell transplantation: barriers and facilitators for medication adherence : O175
Different strategies of chemotherapy-induced nausea and vomiting (CINV) prevention in multiple myeloma patients after autologous hematopoietic stem cell transplantation: a single center experience : O176
Busulfan pharmacokinetics (PK): is it different in patients with fanconi anemia? : O177
Treosulfan-based conditioning in pediatric hematopoietic stem cell transplantation: a prospective study on treosulfan exposure and clinical outcome : O178
Monitoring voriconazole pharmacogenomics and plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients:-a single center experience : O179
Specific cell-therapy for reducing relapse risk after allo HCT : WP001
Acute myeloid leukemia with FLT3 mutation: a therapeutic window for targeted therapy after allogeneic hematopoietic cell transplantation (alloHCT) : WP002
Is there a role for allogeneic stem cell transplantation for t(3;3) (q21;q26)/inv(3) (q21;q26) acute myeloid leukemia? A report from the ALWP of the EBMT : WP003
Translating recent cancer genome discoveries to patient tailored clinical intervention protocols : WP004
Bad cytogenetic leukemia: transplant or not? : WP005
Plasma cell depletion strategies in autoimmune disease : WP006
Northwestern university experience of HSCT for multiple sclerosis—what has been learned in the last 20 years? : WP007
Hematopoietic stem cell transplantation in Crohn's disease : WP008
HSCT in autoimmune diseases (ADs): activity and trends within the first 20 years of the EBMT ADWP : WP009
IMiDs, proteasome-inhibitors and antibodies as part of a transplant-package for multiple myeloma : WP010
JAK inhibitors before, during and after stem cell transplantation for myelofibrosis : WP011
BTK, BCL2 or PI3K inhibitors combined with allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia : WP012
HSCT for adult cerebral adrenoleukodystrophy : WP013
HSCT for SCID in the 21st century: an update from SCETIDE : WP014
HSCT for monogenic autoimmune disorders : WP015
Infectious diseases (IDWP): How much should we worry about viral respiratory tract infections in HSCT recipients? : WP016
Introduction to activities and initiatives of infectious diseases working party EBMT : WP017
Outcome of children developing grade III-IV acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation : WP018
Progress in pediatric chronic graft-versus-host disease (cGvHD) biomarkers : WP019
Previously published : WP020
Outcome of children developing grade III-IV acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation : WP021
Hypomethylating agents pre- and post-transplantation for MDS : WP022
Absolute immature platelet count may predict the platelets graft in patients undergoing ALLO-HSCT : P001
Analysis of genetic polymorphism for cardiovascular diseases (CVD) in placental and maternal blood in hypertension and hypercholesterolemia : P002
Automated red blood cell depletion in ABO incompatible grafts in the pediatric setting : P003
Building up a hematopoietic stem cell transplantation program in a public hospital in Uruguay: International cooperation and development program : P004
Previously published : P005
Correlation between miRNA expression and the level of proangiogenic cytokines in autologous hematopoietic stem cell transplantation : P006
Exclusion of Trypan blue exclusion test for CD34+ cell viability determination : P007
Previously published : P008
Previously published : P009
Improved outcomes of unrelated umbilical cord blood transplantation in children with chronic granulomatous disease: results of a single center in China : P010
Influence of muscle mass and visceral fat (evaluated by ultrasound) and of muscular strength on the engraftment time in patients undergoing hematopoietic stem cell transplant (HSCT) : P011
Inpatient exercise therapy vs relaxation and mental training in pediatric stem cell transplantation: Results of the RCT BISON : P012
Lymphocyte recovery and long-term outcome in allogeneic hematopoietic stem cell transplantation : P013
Mesenchymal stem cell chimerism following HSCT : P014
Morphine consumption during hematopoietic stem cell transplantation strongly correlates with systemic inflammation in pediatric patients : P015
The prevalence of human pegivirus in recipients of allogeneic hematopoietic stem cell : P016
Quantification of CD31+ recent thymic emigrants and T cell receptor excision circles (TRECs) in umbilical cord blood transplanted patients : P017
Remission after allogeneic hematopoietic stem cell transplantation in a patient with LPS-responsive beige-like anchor (LRBA) gene mutation : P018
Second haploidentical stem cell transplantation as a salvage therapy for children with acute leukemia relapsed after first allo-HSCT : P019
Successful unrelated umbilical cord blood transplantation with reduce intensity conditioning for very early onset inflammatory bowel disease: an innovative report from China : P020
TCRαβ and CD19-depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors in pediatric patients with refractory acute myeloblastic leukemia : P021
The JACIE experience at the university hospital of Amiens : P022
Previously published : P023
Three-dimensional co-culture of peripheral blood monocytes supports and expands functional hematopoietic stem/progenitor cell without immobilization : P024
To wash or not to wash? Comparison of neutrophil and platelet engraftment after infusion of cryopreserved autologous stem cells before and after the implementation of bedside thawing : P025
10% DMSO in cryoprotective mixture may be reduced to 5% without negative impact on hematopoietic engraftment. Final results of prospective, randomized trial : P026
A real-world cost-effectiveness analysis demonstrates that introducing Plerixafor to improve mobilization in multiple myeloma patients who behave as poor mobilizers is cost-effective considering the whole mobilization and transplant procedure : P027
Administration of plerixafor for peripheral blood CD34+ stem cell content of <30 × 106/L for autologous stem cell mobilization leads to decreased apheresis days and increased total yield : P028
Previously published : P029
Previously published : P030
CD34+ selected stem cell boosts can improve poor graft function after allogeneic stem cell transplantation in pediatric patients : P031
Combination of plerixafor and G-CSF for mobilization: Impact on engraftment in autologous stem cell transplantation for multiple myeloma : P032
Effects of plerixafor in the lymphocyte count in aphaeresis product : P033
Efficacy and factors influencing peripheral blood stem cell mobilization and collection for the autologous transplantation in patients with lymphoma : P034
Factors associated with failure in mobilization of peripheral blood hematopoietic progenitor cells in autologous transplantation : P035
G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield : P036
Graft purity and composition significantly impact the engraftment of autologous stem cell transplants : P037
Hematopoietic stem cell mobilization: Predicting the unpredictable : P038
Impact of lenalidomide induction in the mobilization of CD34+ cells, blood graft cellular composition and post-transplant recovery in myeloma patients: a prospective multicenter study : P039
Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation : P040
Previouly published : P041
Previously published : P042
Performance evaluation of the spectra optia apheresis system mononuclear cell collection for autologous peripheral stem cell transplantation : P043
Peripheral blood stem cell apheresis in small children is difficult! : P044
Peripheral blood stem cell collection in low body weight children: A single centre experience : P045
Plerixafor on demand in the first or in the second attempt of CD34 mobilization : P046
Pre-clinical validation of Lovo for post-thaw DMSO depletion from cryopreserved stem cells : P047
Priming with G-CSF of the bone marrow grafts in related and haploidentical stem cell transplantations : P048
Priming with granulocyte-colony stimulating factor preserves the contents and abundant IFN-γ production capacity of γδ T cells : P049
Processing of hematopoietic stem cells grafts: Towards automation of cryopreservation/thawing steps : P050
Reduced efficacy of mobilisation using GDP compared to IVE : P051
Single centre experience of ZarzioTM biosimilar Granulocyte-colony stimulating factor (GCSF) for the mobilisation of healthy donors demonstrates good leukapheresis yields and safety profile at 24 month median follow-up : P052
Stem cell mobilization in poor mobilizers with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) before and after introduction of plerixafor: Single center comparative analysis using a cost-efficient single fixed-dose schedule : P053
The choice between stem cell mobilisation with GCSF alone or with GCSF plus chemotherapy may impact on the stem cell transplant service : P054
The comparison of effectiveness and safety between different biosimilar of G-CSFs in mobilization of PBSC of autologous transplantation : P055
Use of G-CSF mobilized bone marrow grafts in HLA-haploidentical related bone marrow transplantation (BMT) with post-transplantation cyclophosphamide (PT-CY) : P056
WBC and CD34+ Kinetics can predict a suboptimal mobilization of hematopoietic stem cells : P057
A new method to generate mature (leukemia-derived) dendritic cells that improve antileukemic T-cell reactivity from mononuclear cells or whole blood from healthy volunteers or patients with AML : P058
A standardized and characterized clinical grade human platelet lysate for optimized expansion of human bone marrow mesenchymal stem cells : P059
Previously published : P060
Alpha/beta T cell depleted donor lymphocyte infusion : P061
Alpha/Beta depletion as a strategy after hematopoetic stem cell transplantation to treat graft failure : P062
Previously published : P063
Bone marrow graft composition and engraftment after HPCT in children : P064
Previously published : P065
Cellular immunotherapy with multiple infusions of ex vivo expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma : P066
Clinical scale production of leukemia specific t-cells from non-transplantable cord blood units : P067
Comparison of two different methods to generate anti-fungal-specific T-cells under pre-clinical-scale conditions : P068
Complete computerization of cell therapy product files (‘zero paper') in the Qap 10 software : P069
Conditioned media from allogenic mesenchymal stem cell culture (MSC-CM) enhances wound healing in an allogenic 3D skin model : P070
Cryopreservation and thawing of hematopoietic stem cells CD34 induced apoptosis through caspases pathway activation : P071
Donor-derived NK cell infusion combined with HLA halpoidentcial blood stem cell transplantation to decrease leukemia relapse for high risk acute myeloid leukemia patients : P072
Donor lymphocyte infusion after haploidentical stem cell transplantation with post-transplant CY : P073
Previously published : P074
Early and sequential CTLA4Ig primed donor lymphocyte infusions (DLI) following post-transplantation cyclophosphamide (PTCY)-based haploidentical PBSC transplantation for advanced hematological malignancies promote proliferation of mature natural killer (NK) cells with cytotoxic potential and markedly reduces relapse-risk without increase in GVHD : P075
Enhanced cytotoxicity of γδ-cytokine induced killer cells against hematologic malignancies : P076
Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial : P077
Feasibility, safety, rapid production and efficacy of institution-produced CD19 CAR T cells in refractory B cell malignancies in Israel : P078
Fostering a public cord blood bank in Jordan: King Hussein cancer center experience and prospective for the future : P079
Functionally active IFN-gamma secreting CMV pp65 specific T cell therapy as an alternative for clinically urgent CMV related diseases : P080
In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells : P081
Increase of polyspecific immune responses against leukemia-associated-antigens (LAA) and reduction of regulatory T cells frequency after donor lymphocyte infusion (DLI) in patients with hematological malignancies : P082
Previously published : P083
Intra bone route of donor lymphocyte infusions in patients relapsing post alloHSCT may result with anti-leukemic effect associated with accumulation of CD279+ lymphocytes and the cells with a distinct TCRbeta clonotype in the marrow : P084
Intra-lesioner autologous stem cell application in diabetic foot/ulcer : P085
Microengrafting HLA-partially matched mobilized cellular therapy (microtransplantation) in elderly patients with acute myeloid leukemia and myelodisplastic syndromes : P086
Modulation of heme oxygenase-1 activity to enhance WT1-specific T-cell responses for immunotherapeutic approaches : P087
Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells : P088
PEG-ADA induced thrombocytopenia in a SCID patient mandating hematopoietic stem cell transplant at late adolescence: A case report and review of literature : P089
PBSC mobilization and apheresis collection for autologous transplantation: Preliminary experience at the Hiwa cancer hospital, Sulaymaniya, Iraqi Kurdistan : P090
PiggyBac transposon, a non-viral gene transfer system, mediated T cells expressing CD19 chimeric antigen receptor for a ‘first in human' clinical trial : P091
Relapse after allo-SCT is associated with high PD-1 and TIGIT expression on tumor-reactive CD8+ T cells : P092
Standardization method to characterize the key parameters influencing the extracorporeal photopheresis efficacy: Towards a better understanding of the procedure : P093
Successful treatment with granulocyte transfusion and early neutrophil engraftment in allogeneic transplant patients with febril neutropenia; do granulocyte transfusions help and accelerate neutrophil engraftment? : P094
Successful generation of human cytomegalovirus (HCMV)-specific T cell lines from immunodeficient patients with refractory HCMV infection or from HCMV-negative donors : P095
The effect of extracorporeal photopheresis on T-cell response in graft-versus-host disease : P096
Therapeutic efficacy of bone-marrow-derived mesenchymal stem cells on acute anthracyclines cardiotoxicity enhanced by microRNA-21-mediated regulation of apoptosis and angiogenesis : P097
Towards adoptive transfer of Akt-inhibited early memory CD8+ T cells for a superior graft-versus-leukemia effect : P098
Use of reversible streptamer technology to isolate clinical grade regulatory T cells from frozen umbilical cord blood units for cell therapy : P099
IL-2 and IL-15 allow the generation of gamma-delta CAR-T cells with potent anti-leukaemia activity: A foundation for off-the-shelf cellular immunotherapy of haematological malignancies : P100
Molecular and functional analysis of mesenchymal stromal cells isolated from the bone marrow of patients affected by beta-thalassemia : P101
Previously published : P102
Donor lymphocyte infusion after haploidentical transplantation with post-transplant cyclophosphamide : P103
Dual specific cytokine-induced killer cell therapy as a treatment option for life-threatening PTLD—a case report of the Frankfurt experience : P104
Extracorporeal photopheresis for treatment of graft versus host disease: The experience of our centre : P105
Ibrutinib as bridge therapy to allogeneic stem cell transplantation in refractory mantle cell lymphoma (MCL): A case report : P106
Inotuzumab ozogamicin and DLI can induce molecular remission in acute lymphoblastic leukemia relapse after allogeneic HSCT : P107
Introduction of the HATCHY study: A Phase III, multicenter, randomised controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101 with post-transplant cyclophosphamide in patients with a hematologic malignancies : P108
Interaction of multipotent mesenchymal stromal cells and lymphocytes : P109
Previously published : P110
Autologous adipose-derived mesenchymal stem cells embedded in platelet-rich fibrin for skin tissue engineering and wound healing : P111
Additionally cryopreserved G-CSF primed PBSC can substitute the second transplantation for the patients with acute leukemia who lately relapsed after hematopoietic stem cell transplantation : P112
Cord blood transplantation—19 years of experience : P113
Cord blood transplantation supported by unrelated donor progenitor cells for patients without haplo-identical relatives : P114
Early withdrawal of immunosuppressive therapy in haploidentical bone marrow transplantation with post-transplantation cyclophosphamide increases chronic GvHD and can reduce relapses : P115
Myeloablative T-cell replete peripheral blood stem cell (PBSC) haploidentical (Haplo) transplant with and without pre-transplant steroid with intermediate and high risk hematological malignancies : P116
Intrabone transplant of unwashed CB in hematological malignancies: engraftment and safety : P117
Lower incidence of cGVHD after cord blood transplantation for hematological malignancies in comparison with hematopoietic stem cell transplantation from other donors: 20 years' experience in a single institute : P118
Patients with chronic active Epstein-Barr virus infection Outcome of umbilical cord blood transplantation in adult patients with chronic active Epstein-Barr virus infection : P119
AB0 incompatibility in allogeneic hematopoietic stem cell transplantation: 15-years experience of R.M.Gorbacheva memorial institute of children oncology, hematology and transplantation : P120
Previously published : P121
Circulating CD34+ cell numbers after re-mobilization of related donors in view of second allo-HSCT or immunoselected allogeneic CD34+ cell infusion (‘boost') are lower to those observed at first mobilization: A single institution retrospective paired analysis : P122
CMV seropositive donor selection for CMV seropositive stem cell transplant recipients reduces CMV reactivation frequency and duration : P123
Comparable outcomes using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: A study from IDWP and ALWP of the EBMT : P124
Comparison of Mismatched Unrelated Donors and Cord Blood to Matched Unrelated Donors in pediatric patients with acute leukemias or myelodisplastic syndromes in Brazil: A multicenter retrospective study : P125
Does matched sibling donor transplantation provide better outcome compared to non-sibling matched family donor in children with hematological malignancies? : P126
Donor-recipient RH incompatibility is a risk factor for mortality after pediatric matched related allogeneic hematopoietic stem cell transplantation : P127
Effect of iron or Vitamin B12 deficiencies on in vitro colony forming capacity of peripheral blood-derived hematopoietic stem cells in children : P128
Efficiency of day 4 compared to day 6 stem cell mobilization in allogeneic donors : P129
Ethnicity is an important determinant of stem cell donation decisions in unrelated donors : P130
Family mismatched allogeneic stem cell transplantation for myelofibrosis: Report from the chronic malignancies working party of EBMT : P131
Feasibility of salvage second allogeneic stem cell transplantation for disease relapse or graft failure: A single centre experience : P132
Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for patients with high-risk hematologic malignancies : P133
Haploidentical T-cell replete transplantation with post-transplant cyclophosphamide and matched unrelated donor for patients with high-risk hematologic malignancies: A single center experience : P134
HLA haploidentical allografting using post transplantation cyclophosphamide in high-risk and advanced MDS and AML patients aged over 50 years: Feasibility and outcome : P135
Key performance indicators to assess the quality of a collection facility: Experience of a single center : P136
Myelodysplasic syndrome of donor cells : P137
NK-cell alloreactivity based on KIR/ligand mismatch in the donor vs recipient direction provides better graft-versustumor effect in patients with active hematological malignancies undergoing allogeneic T-replete haploidentical transplantation followed by post-transplant cyclophosphamide : P138
Post-transplant cyclophosphamide (PT-CY) regimen, following unmanipulated haploidentical bone marrow transplantation post myeloablative conditioning : P139
Public events with an adequate trained medical team represent a valid option for the enrollment of new unrelated donors : P140
The search for hematopoietic stem cell unrelated donors in patients with malignant hemopathies with not-sibling matched family donor: The experience of a center : P141
Sequential gain of mutations in two cases of donor cell haematological malignancy after hematopoietic transplantation revealed by whole exome sequencing. : P142
The impact of donor and recipient sex in allogeneic stem cell transplantation—single center experience (CIC 859) : P143
The Rome transplant network model compared to the Italian bone marrow donor registry activity for unrelated donor search process and transplant efficiency for hematological malignancy : P144
The treatment outcome of hematopoietic stem cell transplantation according to donor types in elderly patients with acute myeloid leukemia : P145
Unrelated transplant for severe aplastic anemia (SAA): Long term results and risk factor analysis for overall survival : P146
Use of haploidentical stem cell transplantation continues to increase, the 2015 European society for blood and marrow transplant activity survey report : P147
Previously published : P148
Immune modulation of activated lymphocytes by human bone marrow mesenchymal stromal cells derived exosomes : P149
Immunomodulatory effect of polyphenols obtained from olive oil in acute graft versus host disease : P150
Immunomodulatory effects of extracorporeal photopheresis in patients with GvHD : P151
Impact of Th17 cells on xenogeneic graft-versus-host disease : P152
Previously published : P153
Metagenomic analysis of gut microbiota in pediatric allogeneic stem cell transplantation underscores marked differences in patients with GVHD : P154
Protection of intestinal epithelial cell damage with aryl hydrocarbon ligand reduces intestinal GVHD in mice : P155
Simvastatin ameliorates graft-vs-host Disease by regulating angiopoietin-1 and angiopoietin-2 in a murine model : P156
Two-year results of prospective trial of risk-adapted graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in related, unrelated and haploidentical stem cell transplantations : P157
A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of graft-versus-host disease : P158
Previously published : P159
A single center research for outcome in patients receiving imatinib for steroid-refractory chronic GVHD after allogeneic stem cell transplantation : P160
Analysis of REG3α as biomarker of gastrointestinal acute graft-versus-host-disease after nonmyeloablative HLA-haploidentical SCT with high-dose post-transplantation cyclophosphamide : P161
Anti-fibrotic treatment with pirfenidone in patients with GvHD-associated bronchiolitis obliterans syndrome : P162
Anti-thymocyte globulin (ATG) dose of 4.5 mg/kg vs 7.5 mg/kg did not result in a significant difference in the incidence of moderate to severe chronic graft vs host disease in allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donor : P163
Anti-thymocyte globulin (ATG) significantly reduces the incidence of moderate to severe chronic graft versus host disease in allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched sibling donor : P164
ATOS: A prospective multicenter non interventional observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation in adults with haematological malignancies : P165
Baseline calprotectin as a predictor for acute gastrointestinal graft versus host disease (GVHD)—a prospective study : P166
Calcinuerin inhibitor (CI) free graft-versus-host disease (GvHD) prophylaxis: Its effects on resource utilization, renal function, and the cost of care : P167
Cannabinoids in the management of chronic GVHD—experience of a center : P168
Characterization of GVHD and its risk factors in patients undergoing allogeneic haematopoietic progenitor cell transplantation : P169
Previously published : P170
Ciclosporin toxicity: Increased mortality and incidence of chronic GvHD after stopping Ciclosporin A and replacing it with mycophenolate mofetil as prophylaxis for GvHD : P171
Clinical impact of different anti-thymocyte globulin doses as GVHD prophylaxis in patients receiving stem cell transplantation from unrelated donors : P172
C-reactive protein levels at acute GVHD diagnosis predict steroid-resistance, treatment related mortality and overall survival after allogeneic hematopoietic stem cell transplantation : P173
CXCR3 autoantibodies and ligands in acute GVHD—bridging endothelial and T cell pathology : P174
Does pretransplant imatinib treatment influence chronic GvHD occurrence? Ph positive vs Ph negative acute lymphoblastic leukemia patients preliminary comparative analysis on behalf of polish adult leukemia group : P175
Dose dependent association of early red blood cell transfusion with increased risk of graft versus host disease and worse survival after allogeneic hematopoietic stem cell transplantation : P176
Early high umbilical cord blood CD3 chimerism associated with acute GVHD at time of onset in haplo-cord transplantation : P177
Effect of single nucleotide polymorphism (SNP) in the interleukin-6 receptor gene on serum levels of CRP, IL-6 and soluble IL-6R and on the outcome after allogeneic stem cell transplantation : P178
Previously published : P179
Efficacy of mycophenolate mofetil at low dose vs high dose in a triple immunosuppressive regimen in allogeneic hematopoeitic stem cell transplant : P180
Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease : P181
Evaluation of various therapeutic strategies in management of sclerodermatous chronic graft-versus-host disease including extracorporeal photopheresis, imatinib and sirolimus- multicentre retrospective analysis of polish adult leukemia group (PALG) : P182
Previously published : P183
Extracorporeal photopheresis (ECP) impacts on GvHD-relevant but not virus-specific and anti-leukemic immune cells : P184
Extracorporeal photopheresis affects dendritic cells by reducing total numbers and blunting cytokine production in patients with graft versus host disease : P185
Extracorporeal photopheresis as early second-line treatment for patients with steroid-dependent or refractory acute graft-versus-host disease: a single-centre experience : P186
Extracorporeal photopheresis for treatment of chronic graft versus host disease : P187
Faecal calprotectin as non-invasive marker for graft versus host disease after paediatric allogeneic haematopoietic stem cell transplantation: an interim analysis : P188
First-line extracorporeal photochemotherapy (ECP) for acute GvHD after allogeneic stem cell transplantation : P189
Graft-versus-host disease in a child with neuroblastoma after autologous bone marrow transplantation : P190
Graft-versus-host disease in paediatric hematologic malignancies receiving best unrelated donor BMT compared to ex vivo T-cell depleted haploidentical stem cell transplant : P191
GVHD and circulating endothelial cells: it takes two to tango : P192
High-dose cyclophosphamide for GVHD prophylaxis in mismatched unrelated donor transplantation : P193
High transplanted CD34+ cells are not associated with beneficial effect on graft-versus-host disease-free, relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation : P194
Imatinib associated with extracorporeal photopheresis can fully reverse severe sclerotic-type lesions in patients with chronic graft-versus-host disease: the Lille University Hospital experience : P195
Impact of acute graft versus host disease development on overall survival in acute myeloid leukemia : P196
Impact of age on transplant-related mortality in patients with acute and/or chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for hematological malignancies : P197
In vivo effects of Nilotinib on lymphocyte subpopulation and function following allogeneic stem cell transplantation : P198
Previously published : P199
Infectious gastro-enteritis after allogeneic hematopoietic transplantation after reduced intensity conditioning (allo-RIC): incidence and possible role in gastro-intestinal acute GVHD : P200
Long-term efficacy of extracorporeal photopheresis in chronic graft versus host disease : P201
Long-term outcome of NIH response criteria in 28 patients receiving imatinib for refractory chronic GVHD : P202
Low early doses of ATG are effective in GVHD prevention in unrelated myeloablative stem cell transplants for acute leukemia and myelodysplasia : P203
Mesenchymal stem cells for the treatment of steroid refractory graft versus host disease after allogeneic stem cell transplantation : P204
Methotrexate day +1 omission is not associated with higher incidence of acute graft-versus-host-disease : P205
Outcome of refractory graft versus host disease (GVHD) treated with extracorporeal photopheresis (ECP) as second line: a single-center experience : P206
Outcomes of co-transplantation of mesenchymal stem cells and hematopoietic stem cells compared to hematopoietic stem cell transplantation alone in ß-thalassemia patients : P207
Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis : P208
Post-transplant cyclophosphamide and bortezomib vs calcineurin inhibitor-based GvHD prevention: comparison of two quasi-contemporaneous matched group : P209
Prevalence of clostridium difficile and acute graft-versus-host disease in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation : P210
Profiles of IL-17, IL-6, IL-8, IFN-γ and TNF-α in allogeneic stem cell transplantation with posttransplant cyclophosphamide : P211
Promising efficacy and safety profile of ruxolitinib in highly pre-treated chronic GvHD patients : P212
Previously published : P213
Ruxolitinib in children with steroid-refractory severe acute enteral GvHD : P214
Ruxolitinib plus extracorporeal photopheresis (ECP) may increase response in steroid refractory acute graft-versus-host disease (aGVHD) : P215
Ruxolitinib treatment for corticosteroid-resistant acute intestinal GVHD : P216
Safety and efficacy of low-dose methotrexate for the treatment of refractory sclerodermatous chronic graft-versus-host disease: a single institution retrospective study : P217
Successful outcome after extracorporeal photochemotherapy (ECP) in persistent refractory chronic graft versus host disease (cGVHD) : P218
Successful treatment of steroid-refractory acute gastrointestinal graft-versus-host-disease by fecal microbiota transplantation : P219
Tear film proteomics reveals important differences between patients with chronic ocular GvHD and healthy controls : P220
The restoration of naive recipient immune system in steroid-dependent cGvHD treatment: a clinical case : P221
The role of 18F-FDG PET/CT as a non-invasive modality in the diagnosis of acute gastrointestinal graft versus host disease (GI-GvHD) in children : P222
The role of stromal dysfunction in oral chronic GVHD : P223
Thymic stromal lymphopoietin levels after hematopoietic stem cell transplantation predicts chronic graft-versus-host disease : P224
Thymopoiesis following HCT: a retrospective review comparing interventions for aGvHD in a paediatric cohort : P225
Treatment of steroid-refractory AGVHD (SR-AGVHD): results in a single center : P226
Previously published : P227
Variable levels of suppressor function in granulocytic myeloid-derived suppressor cells in patients receiving extracorporeal photopheresis for chronic graft-versus host disease : P228
Previously published : P229
A retrospective study of central nervous system invasive fungal disease after allogeneic stem cell transplantation: risk factors, clinical characteristics and outcomes : P230
Activity of brincidifovir against adenovirus (ADV) infection in pediatric population after allogeneic stem cell transplantation: report of the French experience about 20 cases : P231
Actualization of CMV reactivation in hematopoietic stem cell transplant: haploidentical vs non-haploidentical donor transplant group (two-center experience) : P232
Allogeneic stem cell transplantation in patients with HIV infection : P233
Analysis of risk factors influencing course and outcome of clostridium difficile infection in children undergoing hematopoietic stem cell transplantation : P234
Antifungal prophylaxis in high-risk paediatric patients with haematological malignancies: a monocentric experience : P235
Antifungal prophylaxis with micafungin and bridging to inhaled liposomal amphotericin B after engraftment in patients undergoing allogeneic hematopoietic stem cell transplantation : P236
Antifungal prophylaxis with nebulized liposomal amphotericin B and fluconazole is effective and safe in the early phase of allogenic hematopoietic stem cell transplantation : P237
Bacterial isolates and bacterimias following autologous peripheral stem cell transplantation (APSCT) in multiple myeloma (MM) and diffuse large B cell non-Hodgkin's lymphoma (DLBCL): a single center experience : P238
Previously published : P239
Blood culture number is related to microbiological documentation rate of febrile episodes in patients undergoing autologous stem cell transplantation: single-centre experience in 66 consecutive procedures : P240
Candida is an emerging pathogen beyond the neutropenic period of allogeneic hematopoietic cell transplantation : P241
Ciprofloxacin prophylaxis for the prevention of neutropenic sepsis following allogeneic stem cell transplantation : P242
Clinical outcomes of fecal microbiota transplantation for overcoming multidrug resistant infection complications after haploidentical hematopoietic stem cell transplantation : P243
CMV, EBV and HHV-6 reactivation after allogeneic stem cell transplantation does not linked to viral contamination of apheresis platelet concentrates : P244
Previously published : P245
Conventional respiratory virus infections after stem cell transplantation: risk factors, outcomes and changes over time : P246
Cost effective outcome comparison of hematopoietic stem cell transplant performed in HEPA and non-HEPA filter rooms: experience from a single center in India : P247
Cytomegalovirus pneumonitis complicated by a central peribronchial pattern of organising pneumonia : P248
Cytomegalovirus reactivation in pediatric acute leukemia after stem cell transplantation has an effect on relapse and survival in AML but not in B-precursor ALL : P249
Dental status does not predict infection during stem cell transplantation: a single-center survey : P250
Early experience with CliniMACS prodigy CCS method in generation of virus-specific T-cells for pediatric patients with severe viral infections after hematopoietic stem cell transplantation : P251
Early removal of central venous catheter is associated with lower rates of febrile episodes and infective complications in early post transplant period after stem cell transplantation : P252
Previously published : P253
Efficacy of antibiotic therapy during autologous stem cell transplantation: can biochemical markers help us? : P254
Enterovirus related immune reconstitution inflammatory syndrome (IRIS) following haploidentical stem cell transplantation in an MHC class II deficient child : P255
Epidemiology and risk factor assessment of PTLD in a pediatric stem cell transplantation unit: a single centre experience : P256
Infections in patients treated with autologous peripheral hematopoietic stem-cell transplantation : P257
Fluconazole was equal to mold-active drugs in preventing early invasive fungal disease after allogeneic stem cell transplantation regardless of transplantation type : P258
HBV reactivation despite antiviral prophylaxis in haematological patients: results after 2 years of monitoring : P259
Hemorrhagic cystitis: a review of our experience : P260
Herpes simplex virus (HSV) infection in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) : P261
How hematopoietic stem cell transplantation affects the acquired immunity of immunopreventable diseases : P262
Impact of cumulative steroid dose on infectious diseases after allogeneic hematopoietic cell transplantation : P263
Impact of different T-cell depletion techniques on the incidence of infectious complications after allogenic hematopoietic stem cell transplantation : P264
Impact of previous invasive fungal infections on the outcome of patients undergoing allogeneic hematopoietic stem cells transplantation : P265
Previously published : P266
Incidence and risk factors of invasive aspergillosis infection in patients undergoing haploidentical stem cell transplantation after prophylaxis with micafungin and oral triazole : P267
Intractable abdominal pain as first clinical symptom of VZV reactivation in patients after allogeneic stem cell transplantation: case report and review of the literature : P268
Intravesical cidofovir application in BK-virus cystitis after allogeneic hematopoietic stem cell transplantation (HSCT) is safe and highly effective : P269
Intravesical cidofovir is an effective treatment of BK-virus positive haemorrhagic cystitis in post stem cell transplant patients: experience in Leeds Children's Hospital, UK : P270
Previously published : P271
Multiple peptide vaccination against cytomegalovirus (CMV) elicits immunological and clinical responses after allogeneic stem cell transplantation even from a CMV seronegative donor : P272
Necrotic lymph-node infection with sporopachydermia cereana in a patient with acute myeloid leukemia: a case report : P273
Neutropenic enterocolitis incidence after autologous stem cell transplantation : P274
Neutrophil transfusions in the treatment of neutropenic patients submitted to allogeneic HSCT: possible role on graft failure : P275
Oral health status and risk of bacteremia in patients undergoing myeloablative allogeneic hematopoietic cell transplantation : P276
Poor absorption of Atovaquone in stem cell transplant patients: a cause of failure of pneumocystis prophylaxis? : P277
Presepsin as a marker of infectious complications during high-dose chemotherapy following autologous hematopoietic stem cell transplantation in lymphoma patients : P278
Prospective analysis of BK viremia: increases hemorrhagic cystitis (HC) incidence in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) : P279
Prospective study comparing neutropenic enterocolitis in 147 lymphoma patients transplanted with beam vs feam: the role of ultrasound on incidence, diagnosis, treatment and outcome in this life threatening complication : P280
QuantiFeron-CMV in the evaluation of CMV-specific immunity after autologous and allogeneic HSCT : P281
Recovery of Vδ2+ γδ T cells is critical to Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation : P282
Risk factors for pre-engraftment bloodstream infections after hematopoietic stem cell transplantation. Single-centre experience : P283
Septic episodes with multiple bacterial strains during anti-thymocyte globulin (ATG) therapy for conditioning for allogeneic stem cell transplantation under rifaximin gut decontamination : P284
Previously published : P285
Sometimes it is a zebra: rare mycobacterium genavense infection mimicking relapse of T-cell lymphoma after allogeneic hematopoietic stem cell transplantation (HSCT) : P286
Stratification of patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplantation in term of antifungal prophylaxis : P287
Successful management of CNS scedosporium infection after HSCT for aplastic anemia : P288
Previously published : P289
The effect of donor Epstein-Barr virus (EBV) seropositivity on graft versus host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) : P290
The UMC Utrecht pediatric experience with brincidofovir after allo HSCT : P291
Three cases of Herpes virus reactivation after allogeneic stem cell transplantation : P292
Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists : P293
Treatment with brincidofovir for adenovirus disease in pediatric hematopoietic transplants : P294
Viral microneutralization assay to determine seasonal influenza vaccine immunogenicity in the first year post reduced intensity conditioning allogeneic HSCT : P295
Previously published : P296
Systematic assessment of iron overload and confirmation of efficacy and safety of deferasirox in post-allo-HSCT setting : P297
A case-control study of risk factors of primary graft failure with a focus on associated early-onset severe infections : P298
Abnormal cervical cytology and allogeneic stem cell transplantation : P299
Previously published : P300
Acute kidney injury after nonmyeloablative allogeneic stem cell transplantation for lymphoma : P301
Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: long-term follow-up and prognostic factors : P302
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced age adults: is it possible to transplant safely? : P303
Allogeneic stem cell transplantation at-home program, experience and safety in hospital clinic of Barcelona : P304
An increase in RDW-SD after allogeneic hematopoietic transplantation is associated with a poor prognosis : P305
Assessment of impact of hematopoietic stem cell transplant on sickle cell disease burden index : P306
Previously published : P307
Autologous serum preparations for treatment of ocular lesions in chronic graft versus host disease: a 12-year single-centre experience : P308
Biomarkers for idiopathic pneumonia syndrome after hematopoietic cell transplantation: predictors for occurrence and survival : P309
Body composition changes in stem cell transplantation: the case of lymphoma patients : P310
Bone complications following hematopoietic cell transplantation : P311
Changes in intensive care for stem cell transplant patients: the need for response criteria at 5 days of full treatment to separate good risk patients and avoid futile interventions : P312
Chronic GvHD as an independent risk factor for thromboembolic complications after allogeneic stem cell transplantation : P313
Previously published : P314
Clinical presentations and management of isolated extramedullary relapses after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia: an updated single-institute analysis of 378 patients : P315
Previously published : P316
Comparison of various diagnostic criteria of thrombotic microangiopathy after stem cell transplantation : P317
A comparison of the predictive value of the HCT-CI index and the EBMT score to assess the overall survival, relapse incidence and non-relapse mortality in hematopoietic stem cell transplantation: a single center experience : P318
Conception and pregnancy outcomes after haemopoietic stem cell transplant: a retrospective study from the quality of life and complications working party : P319
Danaparoid reduces the transplant related mortality for stem cell transplantation in children : P320
Deferasirox restores hematopoiesis in poor graft patients after allogeneic hematopoietic stem cell transplantation : P321
Previously published : P322
Delayed onset subacute atypical hemolytic uremic syndrome (aHUS) post allogeneic stem cell transplantation (SCT) : P323
Donor complement gene abnormalities cause transplant associated microangiopathy after allogeneic bone marrow transplantation : P324
Donor-specific anti-HLA antibodies and primary graft failure risk in mismatched hematopoietic stem cell transplantation : P325
Early complications and late effects and quality of life at myeloma multiplex patients : P326
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease : P327
Early toxicity because of infectious complications not relapse is the main cause of death after allogeneic transplantation in aplasia for patients with refractory or relapsed acute myeloid leukemia : P328
Eculizumab treatment of transplantation-associated thrombotic microangiopathy: added value of timely determined terminal complement activity and eculizumab drug level monitoring : P329
Efficacy and safety of biosimilar Filgrastim (Zarzio) after autologous stem cell transplant: a prospective study with historical comparison with Lenograstim and Peg-Filgrastim : P330
Eltrombopag induces responses in post allo-HSCT poor graft function : P331
Engraftment syndrome (ES): identification of risk factors : P332
Evolution of weight and nutritional parameters in patients undergoing hematopoietic stem cell transplant : P333
Factors predicting graft versus host disease-free, relapsefree survival after allogeneic stem cell transplantation: comparison attending to two different definitions of ‘chronic graft versus host disease event' : P334
Previously published : P335
Hematopoietic stem cell transplant associated thrombotic microangiopathy and acute graft-versus-host disease : P336
Hemorrhagic cystitis after unmanipulated haploidentical bone marrow transplantation with post-transplant cyclophosphamide : P337
High-dose methylprednisolone (HDMP) for the treatment of sinusoidal obstruction syndrome (SOS) in adults : P338
Hypertension in children treated with hematopoietic stem cell transplantation : P339
Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukaemia : P340
Immunomodulatory effects of prophylactic use of ursodeoxycholic acid in allogeneic stem cell transplantation: survival analysis and potential impact on graft versus host disease : P341
Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation with refractory and relapsed acute lymphoblastic leukemia : P342
Previously published : P343
Impact of previous admission into an intensive care unit on stem cell transplantation outcome : P344
Improvement of outcome after autologous stem cell transplantation by reduction of infections and SOS/VOD syndrome's related mortality: 28 years single-center experience : P345
Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of Turkish Hematology Research and Education Group (ThREG) : P346
Incidence and risk factors for the development of hemorrhagic cystitis on haploidentical transplantation : P347
Previously published : P348
Late onset transplantation-associated thrombotic microangiopathy: a single-centre analysis of incidence and risk factors in allogeneic stem cell transplantation recipients : P349
Long-term outcome of ventilated pediatric hematopoietic stem cell transplantation recipients : P350
Long-term surveillance data support lack of increase in mortality or cancer risk in brincidofovir clinical trial participants : P351
Malignancies after long follow-up of pediatric HSCT: a single-centre experience : P352
Microalbuminuria in long-term survivors of hematopoietic cell transplant: a retrospective single-centre study : P353
Missed and uncontrolled arterial hypertension in long-term survivors after allogeneic hematopoietic stem cell transplantation : P354
Muscle-specific kinase antibody-associated myasthenia gravis post allogeneic stem cell transplantation—successful treatment with rituximab and plasma exchange alone : P355
Previously published : P356
Optimal cooling temperature to prevent adverse effects of chemotherapeutic agents : P357
Outcome following second allogeneic hematopoietic cell transplantation: a single-centre experience : P358
Outcomes of allogeneic stem cell transplantation (alloSCT) for myeloid malignancies in patients over 60 years of age: a single-centre experience : P359
Patients and clinicians communication: do we agree when we talk about quality of life? : P360
Previously published : P361
PICC (peripherally inserted central catheter) is a valid device alternative to standard central venous catheter in patients submitted to autologous stem cell transplantation : P362
Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes : P363
Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) are associated with poorer outcome after single mismatch unrelated donor stem cell transplantation: a study of the German Cooperative Transplant Study Group (GCTSG) within the German working group for bone marrow and blood stem cell transplantation (DAG-KBT) : P364
Pre-transplant evaluation of liver dysfunction including elastography in patients receiving allogeneic hematopoietic cell transplantation : P365
Pretransplant lung function and performance status as mortality predictors after allogeneic hematopoetic stem cell transplantation: a single-center cohort study : P366
Prophylactic recombinant thrombomodulin prevents hepatic veno-occlusive disease/sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants : P367
Protective effect of early human cytomegalovirus reactivation on relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation : P368
Quality of life and donor—recipient relationship after HLA-matched sibling hematopoietic stem cell transplantation—methods and preliminary results : P369
Rate of re-admission in patients undergoing allogeneic transplants from identical siblings, unrelated donors or haploidentical donors : P370
Previously published : P371
Recombinant human thrombopoietin (rhTPO) for treatment of prolonged thrombocytopenia after allogeneic stem cell transplantation : P372
Reproductive health in long-term female survivors after allogeneic hematopoietic stem cell transplantation : P373
Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient : P374
Severe cytokine release syndrome after T-cell replete haploidentical transplantation with post-transplant cyclophosphamide is associated with increased death rate : P375
Sexual functioning during the first year post-transplant: comparison between allogeneic and autologous survivors : P376
Significant improvement of QoL by using ATG as part of the conditioning regimen followed by HLA-identical peripheral stem cell transplantation in acute leukemia patients. Results from a prospective, randomized phase III study (ATG family study) : P377
The impact of oral mucositis on the quality of life of stem cell transplanted patients : P378
Software-based image analysis of CT scans in patients after allogeneic stem cell transplantation for pulmonary chronic ‘graft-versus host' disease diagnosis : P379
The choice of effectiveness criteria affects conclusions of economic evaluation of newer allogeneic bone marrow transplantation modalities: example based on a randomised multicenter trial comparing two reduced intensity conditioning regimen (FLU-BU-ATG) vs (FLU-TBI) for matched related allo-SCT : P380
The impact of corticosteroids prophylaxis for the engraftment syndrome incidence during autologous stem cell transplantation in multiple myeloma and amyloidosis : P381
The incidence and outcome of post-transplant lymphoproliferative disorders do not limit the use of low/intermediate-dose ATG if systematic and close monitoring of EBV viremia is performed : P382
The outcome of haploidentical hematopoietic cell transplantations : P383
The third month risk factor score: detection of disease at day +100 of allogeneic stem cell transplantation is the most important risk factor of worse prognosis : P384
Therapeutic potential of recombinant human soluble thrombomoduline alpha for SOS/VOD: a retrospective analysis in Toranomon Hospital, Japan : P385
Thrombopoietin receptor agonists for delayed and prolonged clinically-relevant severe thrombocytopenia after allogeneic hematopoietic stem cell transplantation : P386
Thrombotic microangiopathy after allogeneic stem cell transplantation—comparison of currently used treatment concepts in adult patients : P387
Tocilizumab as an effective treatment in cytokine release syndrome as an early peri-transplant complications in patients subjected to allogeneic stem cell transplantation-proinfammatory/autoimmune patient/donor HLA haplotype life-threatening early allogeneic HSCT complication risk factor hypothesis : P388
Transplant-associated thrombotic microangiopathy: recognition of patients who would benefit from complement inhibition : P389
Utility of serial biomarkers and serial pulmonary function test for prediction of ICU-admittance/NRM in allogeneic hematopoietic cell transplantation : P390
Very severe hepatic sinusoidal obstruction syndrome continues to be an important cause of mortality after allo-HSCT : P391
Previously published : P392
Alemtuzumab-conditioned unmanipulated stem cell top-up is a safe and effective intervention for poor graft function following allogeneic HPC transplantation : P393
Autologous haematopoietic stem cell transplantation using BEAM ± rituximab for relapsed diffuse large B cell lymphoma in the rituximab era: a 10-year follow-up of a single transplant center in Singapore : P394
Autologous peripheral stem cell transplantation with R/BEAM protocol after modified R/IDARAM/ RT in DLCL with CNS involvement: a single-center experience : P395
Carfilzomib, bendamustine, and melphalan (CBM) conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma is feasible and safe : P396
Previously published : P397
Comparable safety profile of BeEAM (bendamustin, etoposide, cytarabine and melphalan) and BEAM as conditioning before autologous HCT : P398
Comparison of low dose total marrow/total lymphoid irradiation (TMI/TLI) and TBI in haploidentical transplant platform: a retrospective analysis : P399
Comparison of the BeEAM conditioning regimen and the BEAM conditioning regimen in the autologous transplantation for HL and NHL : P400
Conditioning regimen with cisplatin (PEAM) versus carmustine-BCNU (BEAM) followed by autologous haematopoietic stem cell transplantation in lymphoma : P401
Cumulative busulfan exposure is associated with relapse following busulfan and cyclophosphamide myeloablative allogeneic stem cell transplantation for acute myeloid leukaemia : P402
CyBu compared to BuCy conditioning results in lower liver toxicity but does not affect other stem cell transplant characteristics : P403
Early monocyte recovery is associated with better overall survival after busulfan containing myeloablative conditioning allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia : P404
Effect of alemtuzumab dose de-escalation in reduced intensity conditioned unrelated donor haemataopoietic stem cell transplantation for myeloid malignancy : P405
High incidence of HHV-6 infection associated with bendamustine, cytarabine, etoposide and melphalan (BeEAM) conditioning regimen: Results of a monocentric and retrospective study : P406
High-dose treosulfan and melphalan for consolidation therapy in high-risk ewing sarcoma : P407
Immunoadsorption procedures prior to haploidentical allogeneic PBSCT could prevent graft failure in patients with hematological malignancies displaying anti-donor-specific HLA antibodies : P408
Improved outcomes with a novel conditioning regimen in patients with thalassemia major who underwent hematopoietic stem cell transplantation from unrelated donors : P409
Improved overall survival (OS) and reduced frequency of veno-occlusive disease (VOD) in acute myeloblastic leukemia (AML) patients after reduced-toxicity allogeneic stem cell transplantation (SCT) : P410
Low toxicity profile of the combination of carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC) as an alternative conditioning regimen in autologous haematopoietic cell transplantation for lymphoma patients: a single center's experience : P411
Maximal concentration of intravenous busulfan is a determinant of veino-occlusive disease in bone marrow transplanted children : P412
Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation (auto-SCT) as alternative conditioning regimen in Hodgkin's and non-Hodgkin's lymphomas: experience in latin American center : P413
More frequently employed conditioning regimens in allo-HSCT: conventional or reduced intensity but myeloablative : P414
Myeloablative allogeneic stem cell transplant for AML and MDS: the impact of advanced age in the outcome : P415
Radiation-free cytoreductive regimens and T-cell depleted allogeneic stem cell transplants (HSCT) for the treatment of 65 pediatric patients with hematologic malignancies : P416
Reduced intensity conditioning combined with 188Rhenium anti-CD66 radioimmunotherapy for allogeneic hematopoietic cell transplantation in patients with relapsed multiple myeloma : P417
Reduced toxicity conditioning tiotepa-fludarabine-busulfan (TBF) vs fludarabine-busulfan (BF) in HSCT with tacrolimus/sirolimus as GvHD prophylaxis : P418
Reduced-intensity conditioning regimen with fractionated total body irradiation of 6 Gy and cyclophosphamide 60 mg/kg for allogeneic hematopoietic stem cell transplant is well tolerated and offers a potential disease control as treatment of acute leukemia and lymphoproliferative disorders : P419
TBI-based myeloablative conditioning improves engraftment for αβ-T cell depleted haploidentical HSCT in pediatric malignancies : P420
TECAM (thiotepa, etoposide, cyclophosphamide, Ara-c and melphalan) as conditoning regimen for autologous stem cell transplantation in patients with lymphoma : P421
Thiotepa-based conditioning regimens in allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis : P422
Thymoglobuline versus Campath in patients with myeloid disease receiving a reduced intensity conditioning regimen before allogeneic hematopoietic stem cell transplant (HSCT) : P423
Tolerability and safety using fotemustine or thiotepa-based high-dose chemotherapy regimen in Hodgkin and non-Hodgkin lymphoma: a centre report : P424
Toxicological side effects of fludarabin and treosulfan conditioning before allogeneic stem-cell transplantation : P425
Treosulfan, fludarabine and 4Gy TBI conditioning with ATG and sirolimus-based GvHD prophylaxis (TrRaMM4Gy) for haploidentical stem cell transplantation in patients with hematological malignancies : P426
6-color-based HLA-Flow method for the monitoring of minimal residual disease and chimerism after HLA-mismatched allogeneic hematopoietic cell transplantation in children : P427
Cytomegalovirus infection/reactivation promotes faster and stable CD8+ cells immune recostitution and improves survival in acute myeloid leukemia: a single center experience on 122 patients : P428
Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant : P429
Early immune cells subset associated with outcomes after allogeneic stem cell transplantation in childhood patients suffering acute leukemia and myelodysplastic syndrome : P430
Early immune reconstitution impact on overall survival after haploidentical hematopoietic stem cell transplantation : P431
Early lymphocyte recovery predicts prolonged survival after autologous stem cell transplantation for non-Hodgkin lymphoma : P432
Impact of day 100 bone marrow chimerism and subsequent donor lymphocyte infusion on survival in patients with AML/MDS : P433
Impact of early lymphocyte recovery and infused allograft characteristics on relapse in allogeneic transplant recipients for acute leukemia : P434
Influence of mixed chimerism to outcome of allogeneic stem cell transplantation (alloSCT) in patients with non-malignant diseases : P435
Interest of quantitative assessment of hematopoietic chimerism by real-time quantitative polymerase chain reaction after hematopoietic cell transplantation for hematological malignancies: a retrospective analysis on 347 adult patients from Rennes University Hospital : P436
Molecular monitoring of engraftment kinetics and relapse by qPCR-based chimerism after unrelated hematopoietic cell transplantation : P437
Ponatinib post-transplant treatment in patients with high-risk Philadelphia chromosome positive leukemia : P438
Rapid immune reconstitution post CD45RA depleted HSCT leads to better engraftement, reduced risk of invasive viral infections and superior graft versus leukemia effect : P439
Reconstitution of cellular immunity after T-cell replete haploidentical stem cell transplantation by use of post-transplant cyclophosphamide : P440
Stable mixed chimerism after hematopoietic stem cell transplantation in patients with sickle cell disease : P441
Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia in France: a retrospective study of Société Française De Greffe De Moelle Et De Thérapie Cellulaire : P442
Allogeneic hematopoietic stem cell transplantation in patients with pediatric myelodysplatic syndrome and myeloproliferative neoplasms: a single center experience from Turkey : P443
Allogeneic stem cell transplantation in children with autism : P444
Association between conditioning regimen intensity and nutritional aspects in allogeneic hematopoietic stem cell transplantation in children and adolescents : P445
Autoimmune cytopenia following allogeneic hematopoietic stem cell transplantation in pediatric patients : P446
BK polyoma virus disease after allogeneic hematopoietic stem cell transplantation: the experience of single center : P447
Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience : P448
Chimerism evaluation after allogeneic haematopoietic stem cell transplantation in children with non malignant diseases. : P449
Clinical outcome, safety and rapid inmunologic reconstitution in C45RA-depleted haplodentical transplantation in paediatric acute leukemia treatment : P450
Collection of peripheral blood stem cells in teenager sibling donors: a single center experience : P451
Correspondence between clinical and hystological grading of gastro-intestinal grading acute graft versus host disease in children : P452
Current role of hematopoietic cell transplantation in primary immunodeficiencies: a systematic review : P453
Defibrotide for the prevention and treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a single-center experience : P454
Dynamic models of immune reconstitution to predict the risk of infections after allogeneic hematopoietic stem cell transplantation : P455
Early CPAP in the ward prevents evolution of acute lung injury in pediatric HSCT patients : P456
Effectivity of defibrotide prophylaxis on acute graft versus host disease: a single center experience with high risk pediatric patients : P457
First use of mini buffy coat extracorporeal photopheresis for the treatment of graft-versus-host-disease in a low body weight pediatric patient in Croatia : P458
Gonadal function after Busulphan and Treosulfan in children and adolescents undergoing allogeneic haematopoietic stem cell transplantation. On behalf of paediatric and complications and quality of life EBMT working parties : P459
Haploidentical SCT in pediatric patients: a single-centre experience : P460
Haploidentical stem cell transplantation with post-transplant cyclophosphamide or in vivo αβ+T and CD19+B cells depletion: a single-center pediatric experience : P461
Haploidentical stem cell transplantation in children; a single center experience of alpha beta T-cell depleted and unmanipulated transplantation with post-transplant cyclophosphamide : P462
Haploidentical stem cell transplantation with post-transplant HD-cyclophosphamide in children—single center experience : P463
Previously published : P464
Hematopoietic stem cell transplantation in children with thalassemia major: the experience of single center : P465
Hematopoietic stem cell transplantation in MAHAK, (NGO)/2016 report : P466
Hematopoietic stem cell transplantation of pediatric chronic myeloid leukemia in first chronic phase: a multicenter study by the Turkish pediatric bone marrow transplantation study group (TPBMT-SG) : P467
High overall concordance, but discordant absolute level of MRD by flow cytometry and real-time PCR in pediatric ALL : P468
Immune reconstitution inflammatory syndrome in a SCID patient after DLI : P469
Impact of hematopoietic stem cell transplantation on dental development : P470
Importance of body composition in the outcome of hematopoietic stem cell transplantation in elderly patients : P471
Strategies to reduce neutropenic fever and hospital readmission in lymphoma and multiple myeloma patients managed at-home after autologous stem cell transplantation : P472
Is haploidentical transplantation a salvage therapy for pediatric patients requiring urgent transplant? : P473
KIR RL mismatch leads to enhanced NK activation, cytolysis and ADCC in B-lineage precursor ALL : P474
Lomustine-containing conditioning regimen CEM (lomustine, etoposide, melphalan) in autologous stem cell transplant (ASCT) for children with relapsed/refractory lymphomas (single center experience) : P475
Long-term brain status and cognitive functioning in children treated for high-risk acute lymphoblastic leukemia with and without allogeneic hematopoietic stem cell transplantation : P476
Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by haematopoietic cell transplantation: TRUMP data analysis in a collaborative study of The Japan society for haematopoietic cell transplantation : P477
Maternal T-cell engraftment: a first case in an adenosine deaminase (ADA) deficient child : P478
Microbiome dynamics during stem cell transplantation in children using total gut decontamination as graft-versus-host prophylaxis : P479
Minimal residual disease (MRD) pre- and post- HCT for children with AML is highly predictive of event-free survival: a pediatric blood and marrow transplant consortium study : P480
Novel mutations were identified with NGS and Low intensity of conditional regimen succeeded in children with Fanconi anemia who received allo-HSCT : P481
Outcome of alternate donor stem cell transplantation in children: An Indian experience : P482
Outcome of children with ALL in second complete remission transplanted from an unrelated donor: a retrospective analysis : P483
Outcomes of autologous stem cell transplantation with CEAM conditioning in relapsed or refractory Hodgkin's lymphoma : P484
Outcomes of children with hemophagocytic lymphohistiocytosis given allogeneic hematopoietic stem cell transplantation in Italy : P485
Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis (GvHD) in pediatric patients with acute lymphoid leukemia (ALL) transplanted from haploidentical and matched unrelated donors : P486
Previously published : P487
Rapid clearing of the active component of ATG-fresenius compared with ATG-genzyme impacts the immune recovery after allogeneic pediatric HSCT : P488
Reduced toxicity myeloablative conditioning regimen in pediatric hematologic malignancies not associated with improved outcomes : P489
Safety of bacille-carmette-guerin(BCG) vaccination after allogeneic hematopoetic stem cell transplan in children : P490
Single centre experience of harvesting bone marrow from donors <3 years of age : P491
Sinusoidal obstruction syndrome-veno-occlusive disease in pediatric patients given either autologous or allogeneic hematopoietic stem cell transplantation (HSCT). A retrospective study of the AIEOP-SCT (Italian haematology-oncology association-stem cell transplantation) group : P492
Successful allogeneic hematopoietic stem cell transplantation from unrelated donor for DOCK8 deficiency : P493
Successful bone marrow transplantation after myeloablative conditioning in a child with IPEX syndrome : P494
Successful haplo-identical stem cell transplant after αβTCR+ depletion in a patient with interferon gamma receptor 1 deficiency : P495
Tandem autologous stem cell transplantations for high risk pediatric embryonal central nervous system tumors: a single center experience : P496
The diagnostic role of liver stiffness measurement in predicting hepatic veno-occlusive disease (VOD) in pediatric hematopoietic stem cell transplantation (HSCT) : P497
The exact role of extra-corporeal photopheresis in children with GvHD: an unanswered question : P498
Tolerability and responses to ex vivo IL2 activated NK cells from haploidentical parental donors in paediatric patients with refractory leukaemia/lymphoma : P499
Unrelated cord blood transplants for primary immunodeficiency diseases (PID)—Results from a single paediatric center in SE Asia : P500
Unrelated donor peripheral blood stem cell transplantation for children with acquired severe aplastic anemia—should we really avoid this option? : P501
Unrelated peripheral blood stem cell transplantation in four children with dyskeratosis congenita after a fludarabine-based reduced intensity conditioning regimen: A single-center experience : P502
Updated outcome of allogenic haematopoietic stem cell transplatation in autosomal recessive hyper—IgE syndrome due to dock 8 deficiency: Single center experience : P503
Previously published : P504
Excellent outcomes of KIR-ligand mismatched cord blood transplantations in pediatric patients with refractory malignant disease : P505
Impact of FCM-based minimal residual disease on transplant outcomes in patients with AML in hematological complete remission : P506
Post-transplant cyclophosphamide (PTCY) and megadose T cell depleted (TCD) haploHSCT for tolerance induction : P507
A comparative study on the effects of alemtuzumab in the matched unrelated donor (MUD) and sibling donor haemopoietic stem cell transplants (HSCT) settings, after fludarabine-based reduced intensity conditioning (RIC) regimes for high risk (HR) acute myeloblastic leukaemia (AML) : P508
A multicenter retrospective study of allogeneic hematopoietic cell transplantation in blastic plasmacytoid dendritic cell neoplasm : P509
A risk-factor analysis for overall survival in patients with acute leukemia that relapse following T-replete haploidentical transplantation: On behalf of the acute leukemia working party of the european society for blood and marrow transplantation : P510
Previously published : P511
Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia (AML): a retrospective analysis of 537 patients from the acute leukemia working party of the EBMT : P512
An IDA intensified conditioning haploidentical hematopoietic stem cell transplantation with combined GVHD prophylaxis of ATG and basiliximab improve survival for high-risk acute leukemia patients : P513
Analysis of post Allo-HCT relapse in acute leukaemia patients, a comparative on second Allo-HCT and donor lymphocyte infusions : P514
Analysis of survival after allogeneic transplantation by age strata for patients treated with CPX-351 liposome for injection versus cytarabine and daunorubicin 7+3 in patients aged 60-75 years with untreated high-risk acute myeloid leukemia : P515
Previously published : P516
Azacitidine and donor lymphocyte infusion in relapsed AML or MDS after allogeneic stem cell transplant: a single-centre analysis : P517
Case report: a patient with acute myeloid leukemia and dyskeratosis congenita undergoing allogeneic stem cell transplantation: Implications for treatment : P518
Chronic graft-versus-host disease and donor lymphocyte infusions in patients with non-de novo acute myeloid leukemia or advanced myelodysplastic syndromes after allogeneic stem cell transplantation : P519
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation: results from a multicenter survey : P520
Concurrent blinatumomab and donor lymphocytes for relapse of acute lymphoblastic leukemia after 2nd allogeneic transplantation—a case report : P521
Decitabine combined with HAAG regimen is an effective salvage treatment for advanced acute myeloid leukemia : P522
Different pre-transplant conditions, different prognostic impact of FLT3-ITD mutation on the post-transplant survival: a report from Taiwan bone marrow transplant registry (TBMTR) : P523
Extramedular relapse after allogeneic stem cell transplant in myeloid malignancies: A center experience : P524
FLAG-IDA regimen as bridge therapy to allotransplant in refractory/relapsed aml patients: a single-center experience : P525
Germ line c.584-589dup mutation of CEBPA gene strengthens bone marrow niche and increases the survival of AML cells under chemotherapy : P526
Previously published : P527
Hematopoietic stem cell transplantation for childhood leukemia in Mahak : P528
HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients : P529
Immunomodulatory Kits do not induce AML-blasts' proliferation ex vivo : IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts : P530
Impact of additional cytogenetic abnormalities in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation : P531
Previously published : P532
Long term impact of hyperleukocytosis in newly diagnosed AML patients undergoing allogeneic stem cell transplantation in the era of advanced molecular prognostication : P533
Number, composition and/or antileukemic activity of (DC-stimulated) invariant NKT-, NK- and CIK-cells is predictive for outcome of patients with AML, ALL and CLL : P534
Outcome after hematopoietic stem cell transplantation for Philadelphia-positive AML: relatively favorable outcome in patients allografted in first complete response; a survey from the acute leukemia working party of the European society for blood and marrow transplantation (EBMT) : P535
Outcome of allografting for AML-CR2 is equivalent across the BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups : P536
Outcome of HTLV-1 associated adult T cell leukemia/lymphoma (ATL) w/o allo-HSCT with kinetic monitoring of proviral DNA load in an endemic area in the southeast of China: a consecutive study over 20 years : P537
Previously published : P538
Preliminary haploidentical transplantation experience in a single center : P539
Reduced intensity conditioning (RIC) allografts overcome poor prognosis associated with complex karyotype, FLT-3 ITR and alterations of chromosome 7 in high-risk (HR) acute myeloid leukaemia (AML), yielding results comparable to other indications of allograft for AML patients : P540
Reduced relapse risk in patients with AML after HCMV-replication post transplantation-final results of a prospective registration trial (DRKS00004300) : P541
Results of hematopoietic stem cells transplantation with TCRαβ+/CD19+-depletion from matched unrelated and haploidentical donors in pediatric acute myeloblastic leukemia patients in complete remission : P542
Results of T-cell depleted haploidentical stem cell transplantation in adults with acute leukemia improve with time: a study from the acute leukemia working party of the European society of blood and marrow transplantation (EBMT) : P543
Sequential conditioning and haploidentical transplantation produces long-term survival in high-risk AML and is equally effective to HLA-matched SCT—Results of a matched-pair analysis : P544
Sequential fludarabine, Ara-C, etoposide (FLAV) followed by Fludarabine/Busulfan reduced toxicity conditioning is safe and effective salvage for adult patients with refractory acute myeloid leukemia and high risk myelodysplasia : P545
Sequential high-dose chemotherapy reinduction followed by haploidentical transplantation in acute leukemias : P546
Omitted : P547
Sustained molecular remission in an elderly patient with RCSD1-ABL1 positive acute lymphoblastic leukemia enabled by dasatinib and allogeneic stem cell transplantation : P548
Sustained remission with Sorafenib treatment for extramedullary FLT3+-AML relapse after allogeneic stem cell transplantation : P549
TCRαβ+/CD19+-depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors following treosulfan or TBI-based conditioning in pediatric acute lymphoblastic leukemia patients : P550
The efficacy and toxicity of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia: A Russian multicenter experience : P551
The mechanism of sorafenib anti-leukaemic effect seen in AML patients relapsing post alloHSCT involves the augmentation of alloreactivity which includes infiltration of the affected marrow by CD8+ cells having PD-1 receptor which presence characterize lymphocytes with anti-tumour potential : P552
The outcome of elder patients with acute myeloid leukemia or high risk myelodysplastic syndrome treated with allogeneic hematopoietic stem cell transplantation : P553
Transplant program evolution within 30 years and acute leukemia improved outcome : P554
Treatment of refractory pediatric acute lymphoblastic T cell leukaemia with anti-programmed cell death protein 1 (PD-1) antibody after allogeneic stem cell transplantation : P555
Unmanipulated haploidentical-related donor HCT: A single center experience : P556
A feasible way to control infection by hematopoietic stem cell transplantation for children with aplastic anemia and refractory active infections : P557
Aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: intensive immunosuppression and eculizumab treatment. A retrospective analysis from two reference centers : P558
Bone marrow transplantation for children with acquired bone marrow failure : P559
Decreased toxicity of allogeneic matched related donor bone marrow transplantation for pediatric patients with severe aplastic anemia using “low dose” cyclophosphamide, ATG plus fludarabine. A small pilot study and a new standard of care? : P560
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: A study of 976 patients treated 2001-2012 : P561
Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide for severe aplastic anemia complicated with infection : P562
Long-term outcome of patients with severe aplastic anemia receiving allogeneic hematopoietic cell transplantation using nonmyeloablative conditioning with fludarabine and low dose total-body irradiation : P563
Paroxysmal nocturnal hemoglobinuria: A long-term single center experience : P564
Transplantation in patients over 40 with acquired aplastic anemia: Mortality has not been reduced from 2010 to 2015 : P565
Allogeneic haematopoetic stem cell transplantation as curative therapy for early-onset, refractory Crohn's disease : P566
Autologous haematopoietic stem cell transplantation (AHSCT) for Crohn's disease (CD): A retrospective study of outcomes from the EBMT autoimmune diseases working party (ADWP) : P567
CD4+ memory stem T cells: Novel players in Rheumatoid arthritis : P568
EBV and CMV reactivation following autologous haematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases resolves spontaneously and rarely requires treatment : P569
Exacerbation of multiple sclerosis symptoms in patients undergoing autologous stem cell transplantation : P570
Inflammatory immune response after autologous transplantation in neurologic diseases : P571
Long-term outcomes and late effects at children with multiple sclerosis and neuromyelitis optica after hematopoietic stem cell transplantation : P572
Busulfan-fludarabine versus thiotepa-fludarabine as a reduced-intensity preparative regimen for allogeneic haematopoietic stem-cell transplantation in patients with myelofibrosis: A phase II, multicentre, randomized trial : P573
Impact of liver stiffness measured by transient liver elastography (FibroScan) on liver toxicity in myelofibrosis patients undergoing allogeneic stem cell transplantation : P574
Impact of pre-transplant ruxolitinib in myelofibrosis patients on outcome after allogeneic stem cell transplantation : P575
Impact of tyrosine kinase inhibitor (TKI) towards allogeneic haemopoietic stem cell transplantation (allo-HSCT) among multi-ethnic chronic myeloid leukemia (CML) patients: A single Asian centre's experience : P576
Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial : P577
No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties : P578
Outcomes of patients with advanced CML treated with allogeneic hematopoietic stem cell transplantation in the Era of tyrosine kinase inhibitors (TKIs) : P579
Reduced-intensity conditioning with allogeneic stem cell transplantation in 25 patients with high-risk chronic lymphocytic leukemia: Single centre experience : P580
Role of allo-HSCT in the treatment of patients with T315I mutation in the TKI era : P581
Splenomegaly, high DIPSS plus score, ruxolitinib and chronic GvHD independently influence survival after myeloablative allo-HCT in patients with primary myelofibrosis : P582
The role of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients in the TKI-era: A single center experience : P583
Use of first or second generation TKI for CML after allogeneic hematopoietic stem cell transplantation: A study by the CMWP of the EBMT : P584
A treosulphan based protocol for thalassaemia major—graft kinetics in different age groups : P585
Allogeneic hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis (HLH) in adults: A retrospective study of the chronic malignancies and inborn errors working parties (CMWP and IEWP) of the EBMT : P586
Allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for patients with inherited non-malignant diseases : P587
An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), as adjuvant treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major : P588
Changing the shape of sickle cell disease treatment: A hermeneutic study of a case that changed a family and a medical practice : P589
Defibrotide (DF) prophylaxis and adjustment of busulfan schedule to prevent veno-occlusive disease and thrombotic microangiopathy in an infant with a membrane cofactor protein (MCP) gene mutation and metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy (HSC-GT) : P590
Disease-specific conditioning regimen in hematopoietic stem cell transplantation for children with inherited bone marrow failure syndromes : P591
Haploidentical hematopoietic bone marrow transplantation with consecutive living kidney transplantion from the same donor in a sickle cell disease patient with end-stage renal failure : P592
Haploidentical transplantation with post-transplant cyclophosphamide for pediatric non-malignant disorders : P593
Hematopoietic stem cell transplant for sickle cell disease: The Indian experience : P594
Hematopoietic stem cell transplantation for children with thalassemia: A start up cooperative project in Iraqi Kurdistan : P595
Long term follow-up after reduced-intensity conditioning and stem cell transplantation for Thalassemia major : P596
Long-time follow-up and late effects estimation in patients with Hurler syndrome after allogenic hematopoietic stem cell transplantation: Results of Russian joint study : P597
Non PTLD malignancy post-HSCT for primary immunodeficiency—A case series : P598
Non-myeloablative alemtuzumab/low dose total body irradiation conditioning for children undergoing HLA-matched sibling donor haematopoietic cell transplantation for sickle cell disease : P599
Successful allogeneic hematopoietic stem cells transplantation from HLA-identical sibling selected with preimplantation genetic diagnosis (PGD) with HLA matching in a patient with Shwachman-Diamond syndrome (SDS) : P600
The safety and efficacy of familial haploidentical (FHI) stem cell transplantation utilizing CD34 enrichment and CD3 addback in patients with high risk sickle cell disease (SCD) (IND 14359) : P601
A clinical prognostic index for assessing patients aged >60 being considered for high-dose therapy and autologous stem-cell transplant in relapsed or refractory high-grade non-Hodgkin lymphoma : P602
Allogeneic stem cell transplantation (allo-SCT) after treosulfan-based conditioning regimen for B-cell non-Hodgkin lymphoma (B-NHL) : P603
Autologous stem cell transplantation for systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT : P604
Autologous stem cell transplantation in refractory coeliac disease type II—The Irish experience : P605
Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma : P606
Bendamustine: Promising activity in post-brentuximab failure Hodgkin's lymphoma patients who had also failed a prior autologous HCT and possible successful bridging to allogeneic HCT : P607
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma, single center experience king faisal specialist hospital and research center, Riyadh, Kingdom of Saudi Arabia : P608
Effect of HIV infection on transplant outcomes after autologous peripheral blood stem cell transplantation: A retrospective study of Japanese registry data : P609
Efficacy and toxicity of BEAC versus BEAM high-dose chemotherapy in patients with mantle cell lymphoma undergoing autologous stem cell transplantation : P610
Efficacy of allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas in the front-line and relapsed/refractory setting: Results of a systematic review/meta-analysis : P611
High-risk patients with relapse or refractory Hodgkin lymphoma do significantly better after HDC auto-SCT compared to control arm of AETHERA trial. Mature results from a cohort of 234 patients : P612
High-dose melphalane and autologous peripheral blood stem cell transplantation as a salvage therapy for diffuse large B-cell lymphoma refractory to 2nd or 3rd line treatment : P613
High-dose therapy and autologous hematopoietic progenitor cells transplantation for relapsed or refractory Hodgkin lymphoma: A follow up analysis of King Hussein cancer center results and prognostic variables : P614
HIV-related hematological malignancies: A single-center experience : P615
Long term survival of refractory Hodgkin lymphoma after high dose chemotherapy (HDC) and autologous stem cell transplant (ASCT). Single institution analysis of 177 patients : P616
Long-term outcome of reduced intensity conditioning allogeneic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome : P617
Outcomes of allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomas: A retrospective multicenter experience of the rete ematologica pugliese (REP) : P618
Outcomes of both high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation and conventional chemotherapy alone for mantle cell lymphoma: A 12 -year single-center experience : P619
Outcomes of hematopoietic stem cell transplant for extranodal natural killer/T-cell lymphoma, nasal type: A study from the Société Francophone de Greffe de Moelle et de Thérapie cellulaire : P620
Phase I study of myeloablative conditioning regimen of full-dose busulfan, melphalan, and fludarabine for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed aggressive lymphoma : P621
Primary cutaneous T cell lymphoma (CTCL): Long term follow-up after allogeneic hematopoietic stem cell transplant (HSCT) : P622
Results of frontline high dose chemotherapy in high-risk DLBCL patients stratified according to the NCCN-IPI : P623
Salvage treatment of relapsed enteropathy-associated/monomorphic epitheliotropic intestinal T-cell lymphoma using allogeneic hematopoietic cell transplantation (HCT) : P624
Strong graft versus lymphoma effects with low toxicicty of haploidentical hematopoietic stem cell transplantation comparing with HLA-Identical in T cell lymphomas: A retrospective multicenter study : P625
Successful bridge with Ibrutinib monotherapy to allogeneic stem cell transplant in relapsed mantle-cell lymphoma : P626
TEAM conditioning (Thiotepa, etoposide, cytarabine, melphalan) prior to autologous hematopoietic stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: First results from a prospective multicenter study : P627
The cell of origin has no prognostic impact on high-dose chemotherapy with R-beam and autologous stem cell transplant for diffuse large B cell lymphoma : P628
The DICEP regimen effectively reverses the poor outcome for lymphoma patients with suboptimal response or failure post 1st salvage treatment : P629
Treosulfan-based conditioning and sirolimus for prevention of GvHD after allogeneic transplantation in advanced lymphomas: Results in 73 patients : P630
Upfront autologous stem cell transplantation in patients with diffuse large B cell lymphoma: Focused on risk factors for survival and conditioning regimens : P631
Association between grade of response and outcomes in transplant-eligible myeloma patients : P632
Autologous peripheral blood hematopoietic stem cell transplantation in elderly patients with multiple myeloma as a standard therapeutic procedure. Is it feasible? A single-center experience : P633
Autologous stem cell transplantation program for patients with multiple myeloma in an outpatient setting : P634
Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor : P635
Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone : P636
Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience : P637
Calcineurin inhibitor as graft versus host disease prophylaxis in patients with relapsed multiple myeloma undergoing allogeneic stem cell transplantation : P638
CD34+ cell dose is an independent prognostic factor in patients with Hodgkin lymphoma and multiple myeloma who underwent autologous stem cell transplantation : P639
Cost effective outcome of generic medicines used in CyBorD protocol induction and generic Melphalan Autologous transplant conditioning: Experience in 25 patients of multiple myeloma from single center in India : P640
Impact of genetic abnormalities after autologous and allogeneic stem cel transplantation in multiple myeloma : P641
ISS stage and response to prior therapy are more important than maintenance therapy choice in posttransplantation multiple myeloma outcomes : P642
Lenalidomide vs. bortezomib maintenance choice post-autologous haematopoietic cell transplantation (AHCT) for multiple myeloma : P643
Multiple myeloma: Allogeneic or autologous hematopoietic stem cell transplantation? : P644
Myeloablative allogeneic hematopoietic stem cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma : P645
Outcome of 66 allotransplants for myeloma at a single center: Severe acute GVHD and response inferior to CR are the two most critical factors for survival : P646
Overexpression of miR-21 involved in plasma cell myeloma-associated angiogenesis : P647
Pilot study of Busulfan/Thiotepa as conditioning regimen followed by allografting and post transplantation cyclophosphamide in advanced relapsed myeloma patients : P648
Quantitative analysis of T1-weighted MRI images as a surrogate for fat content does not correlate with response or survival : P649
Real-world multiple myeloma management practice patterns and outcomes in six central and Eastern European countries : P650
Safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma : P651
Second autologous stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression : P652
Second autologous stem cell transplantation as treatment option for relapsed patients with multiple myeloma: A single center experience (CIC 859) : P653
Secondary malignancies in patients undergoing autologous hematopoietic cell transplant for multiple myeloma : P654
Survival analysis after allogeneic hematopoietic stem cell transplantation in patients diagnosed with multiple myeloma: A single center experience : P655
The impact of melphalan dosage on outcomes of autologous haematopoietic cell transplantation for multiple myeloma: Results from the EBMT collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study : P656
The outcome of high-dose chemotherapy and autologous stem cell transplantation in transplant-elegible patients with multiple myeloma: A true story : P657
When is the best moment, and which is the best conditioning regimen to use, for the second autologous transplantation in multiple myeloma patients? : P658
Allogeneic haematopoietic stem cell transplantation for elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A single center analysis : P659
Counting bone marrow blasts as a percentage of non-erythroid cells provides superior risk stratification for MDS patients with erythroid predominance : P660
Effect of CD34+ cell dose on outcome of allogeneic hematopoietic stem cell with myelodysplastic syndrome in children and adolescents : P661
Hypomethylating agents vs. Allogeneic sct in elderly patients with advanced myelodysplastic syndromes: A single center study : P662
Immunophenotypic assessment of erythroid dysplasia by a simplified cocktail in myelodysplastic syndromes in Taiwan : P663
Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation (HSCT) for myelodysplastic syndrome (MDS) : P664
Mutational pathway and dynamics may not be prognostic in patients with myelodysplastic syndrome receiving hypomethylating agent pre-treatment for allogeneic stem cell transplantation : P665
Any role of high-dose chemotherapy in mediastinal non-seminoma germ cell tumors? : P666
High dose therapy and autologous stem cell transplantation in gynaecological malignancies: A monocentric retrospective study : P667
The human endogenous retroviruses R, H, K and P (HERV-R, -H, -K, -P) are overexpressed in the tumor of colorectal cancer patients : P668
A Biosimiliar G-CSF filgrastim is as effective as a reference drug however itis not as cost effectiveas it supposed to be and by the way no impact on the health care system : P669
A new mechanism to control ABL tyrosine kinase activity in STIs (Signal transduction inhibitor) treated CML patients via PRX II (Peroxiredoxin II) : P670
Allogeneic hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis : P671
Alternative donor hematopoietic stem cell transplantation using busulfan, fludarabine, and thymoglobulin conditioning for patients with chronic granulomatous disease : P672
Amebiazis in hematopoietic stem cell transplantation: An endemic region analysis : P673
Autologous haematopoietic stem cell transplant in multiple sclerosis: Updated results from the Pan-London MS group : P674
Baseline peripheral blood CD34+ cell count correlates with the effectiveness of allogeneic stem cell mobilization in healthy donors after administration of G-CSF : P675
Clinical analysis of autologous peripheral blood hematopoietic stem cell mobilization regimen in 56 multiple myeloma patients : P676
Clinical efficacy of BK virus specific T-cells in treatment of severe refractory hemorrhagic cystitis after HLA haploidentical transplantation : P677
Comparable outcomes of haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and unrelated donor transplantation : P678
Cryopreservation of peripheral blood stem cells for autologous transplantation in Republic of Macedonia : P679
Effectivity of a fludarabine based conditioning regimen in allogenic hematopoietic stem cell tranplantation for patients with severe aplastic anemia and over twenty years old : P680
Efficacy of hypomethylating agents administration before allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia, myelodisplastic syndrome, juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia : P681
Elucidation of molecular markers for the diagnosis of chronic graft-vs-host disease developing after allogeneic hematopoietic stem cell transplantation : P682
Exergaming has an impact on quality of life after hematopoietic stem cell transplantation—a prospective, randomized study : P683
Expression of serum MicroRNAs is dysregulated during acute graft versus host disease : P684
Factors associated with medication adherence amongst allogeneic hematopoietic stem cell transplantation recipients : P685
Feasibility and efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation for HIV-related lymphoma: A single-institution experience : P686
Fibroblast growth factor and dexamethasone have different effects on impaired immunosuppressive activity of mesenchymal stromal cells in lymphoma patients : P687
Free nonabsorbable antibacterial digestive decontamination is associated with a low incidence of gastrointestinal acute GVHD and better GVHD-free/relapse-free survival (GRFS) in the ATG-based conditioning regimens : P688
G-CSF primed HLA haploidentical transplantation from maternal or collateral donor using ATG plus reduced dose of posttransplantation cyclophosphamide: Results of a phase II prospective trial : P689
Hematopoetic stem cell transplantation comorbidity index in transplant recipients and impact of pulmonary and cardiac function values on its score : P690
Hematopoietic stem cell transplantation for haemophagocytic lymphohistiocytosis: A single- center report of 61 patients : P691
Hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in a single centre: Revised diagnosis and incidence according to new ebmt classification : P692
High dose chemotherapy and autologous stem cell transplantation for patients with high risk or relapsed Ewing sarcoma family of tumors: a single institute experience : P693
High incidence of engraftment syndrome in haploidentical transplant patients with the use of post transplant Cyclophosphamide in Chile : P694
HLA-haploidentical transplantation using T-cell-replete grafts and high-dose cyclophosphamide posttransplantation in the treatment of relapsed/refractory T-cell lymphoma/leukemia : P695
Incidence of secondary primary malignancies (SPM) in patients with multiple myeloma (CALM study) : P696
Interaction between center effect and strategy for GVHD prophylaxis on outcome of T-cell depleted and T-cell replete haploidentical transplant: An analysis on behalf of ALWP-EBMT : P697
Introducing TacroCalc: A tacrolimus dose calculator for android and iOS that promotes therapeutic tacrolimus dosing post allogeneic stem cell transplantation : P698
Investigating frequency of EBV reactivation following autologous HSCT in patients with multiple sclerosis : P699
Investigation and management of bone mineral density following hematopoietic cell transplant: A survey of current practice by the the complications and quality of life working party of the EBMT : P700
Is autologous hematopoietic stem cell transplantation for acute myeloid leukemia still an option? : P701
Lipid profiles after first and subsequent allogenic and autologous stem cell transplantations: 25-year follow up data : P702
Low pre-transplant testosterone levels in male patients are associated with endothelial vulnerability and non-relapse mortality after allogeneic stem cell transplantation : P703
NK cells anti-tumor ability in multiple myeloma patients : P704
NKG2D-CAR redirected CD45RA: Memory T-cells target pediatric acute leukemia : P705
Optimal initial dose of busulfan in infant and child: Comparison of busulfan pharmacokinetics among age groups : P706
Outcome and future perspectives of allogeneic stem cell transplantation in patients with acute myeloid leukemia according to ELN risk : P707
Outcome of allogeneic stem cell transplantation for patients with high-risk acute leukemia according to donor type and graft-versus-host disease prophylaxis : P708
Outcome of second allogeneic hematopoietic stem cell transplant in children with malignant and non-malignant underlying diseases. A Single center retrospective analysis : P709
Outcomes of hematopoietic stem cell transplantation in severe combined immunodeficiency patients with disseminated bacillus Calmette Guerin infection : P710
Paraproteinemia occurrence after allogeneic hematopoietic stem cell transplant as a possible marker for chronic GvHD onset : P711
Peripheral blood stem cell mobilization and collection from elderly patients (≥65 years) with multiple myeloma: A single center experience : P712
Prognostic impact of cytomegalovirus serology in donors and recipients of allogeneic hematopoietic stem cell transplantation for acute leukemia. Single center study : P713
Quality of life (QoL) assessment in multiple sclerosis (MS) patients undergoing autologous hematopoietic stem cell transplantation (AHSCT): does it matter? : P714
Reduced-intensity conditioning hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I: A single center experience : P715
Regulatory T cells (TREGs) GMP production for clinical application: Phenotypic and functional analysis of cryopreserved/thawed healthy TREGs : P716
Relapsed and refractory malignant B cell diseases: Evidence for therapeutic efficacy via subcutaneous administration of anti-CD20 × anti-CD3 antibody lymphomun : P717
Release of antimicrobial peptides in allogeneic stem cell transplantation: Opposing effect of graft-versus-host disease and systemic antibiotics : P718
Results of stem cell transplantation in inherited bone marrow failure syndromes—single center experience : P719
Safety and preliminary efficacy of “Ready to administer” cytomegalovirus (CMV)-specific T cells for the treatment of patients with refractory CMV infection : P720
Safety of dose escalating haploidentical memory T cell donor lymphocyte infusions after 45RA-depleted haplostem cell transplantation : P721
Second haploidentical stem cell transplantation after relapse following first allogeneic transplantation : P722
Secondary solid tumors following hematopoietic cell transplantation for thalassemia major : P723
Sequential treatment with bortezomib plus thalidomide plus dexamethasone followed by autologous hematopoietic stem cell transplantation (HSCT); consolidation and maintenance therapy in patients with multiple myeloma : P724
Serum and extracellular vesicle MicroRNAs miR-423, miR-199 and miR-93* as biomarkers for acute graft-versus-host disease : P725
Simplified validated criteria for donor selection in acute leukaemia : P726
Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation for treatment of myeloid malignancies : P727
The impact of minimal residual disease and its kinetics prior to different types of allogeneic hematopoietic stem cell transplantation on clinical outcomes in patients with acute myeloid leukemia : P728
The retrospective study of allogeneic hematopoietic cell transplantation for 36 patients with mixed-phenotype acute leukemia in Toranomon Hospital, Japan : P729
The role of time gap between first and second allogeneic hematopoietic stem cells transplantations and the effect of donor change in second transplant outcomes in patients with hematological malignancies : P730
The start-up of the first HSCT center in the Iraqi Kurdistan: A cooperative project by the Hiwa cancer hospital, Sulaymaniyah, and the Italian agency for development cooperation : P731
The use of plerixafor with G-CSF in conditioning regimen for hematopoietic stem cell transplantations with TCR alpha/beta and CD19 depletion of graft in Wiscott-Aldrich syndrome patients: A single-center experience : P732
Therapeutic effects of autologous peripheral blood stem cell transplantation on advanced neuroblastoma and childhood rhabdomyosarcoma : P733
Transplantation outcomes of a once-daily intravenous Busulfan and Fludarabine conditioning for Allogeneic hematopoietic stem cell transplantation in pediatric AML and high risk MDS: Single center experience in Korea : P734
Unmanipulated haploidentical hematopoietic stem cells transplantation (HaploSCT) with post-transplant cyclophosphamide: Experience of the hematology and stem cell transplant center of Pesaro, Italy : P735
Wharton's jelly-derived mesenchymal stem cells treatment in children with autism spectrum disorder: Our first preliminary results of the clinical application in Poland : P736
Wharton's jelly-derived mesenchymal stem cells treatment in children with cerebral palsy: Our second preliminary results of the clinical application in Poland : P737
Wharton's jelly-derived mesenchymal stem cells treatment in children with Spina bifida: Our first preliminary results of the clinical application in Poland : P738
Innovation and training: an experience—the transmission of bad news in the context of hematopoietic precursors transplantation : NO001
Investigating patients and caregivers utility and needs for an educational programme dedicated to stem cell therapy for autoimmune diseases : NO002
Journal club for nurses increases awareness and knowledge of evidence based practice : NO003
The Development of the Myeloma Learning Programme : NO004
A Standard Approach to Reducing Haematology/BMT “Never events” and Other Clinical Incidents in a BMT Setting: A Clinical Governance Framework : NO005
Hematopoietic Stem Cell Transplant (HSCT) Nurses Booklet, on behalf the French EBMT nurses group : NO006
Survivorship in ACTion—A Group Intervention To Treat Fear Of Recurrence : NO007
Management of cytomegalovirus infection in a Home Care Unit : NO008
Nursing care in gastro intestinal GVHD : NO009
Hematopoietic stem cell transplant nurse coordinator's (HSCT-NC's) perceptions of related donor care: a European survey : NO010
Out of reach but not out of touch—consultation team hematology : NO011
Nursing Education Programme in Outreach Countries: China 2016 : NO012
Nursing in the shadow of battle: the story of B., a Syrian refugee in Israel : NO013
How Science Can Transmit (HSCT) passion in India: a project by Nurses No Frontiers (NNF) : NO014
The startup of the first HSCT center in the Iraqi Kurdistan: joint work of Hiwa Cancer Hospital (HCH), Sulaymaniah, and the Italian Agency For Development Cooperation (IADC): Nursing Perspectives : NO015
Previously published : NO016
Change of protective isolation in paediatric SCT; from the past to the present and one step back : NO017
Previously published : NO018
The core of sibling stem cell donation—a prospective grounded theory approach : NO019
Some risk factors for complicated grief in parents of children with cancer : NO020
A Room of My Own: Experiences of Hematological Patients undergoing Bone Marrow Transplant in Shaare Zedek Medical Center, Jerusalem : NO021
Evaluation of the nutritional status in allogeneic patients : NO022
Management of infections by multidrug-resistant organisms in Italian Bone Marrow Transplant Units: are there winners or just losers? The Nurses' Group of GITMO investigation : NO023
The quality of sleep in patients undergoing haematopoietic stem cell transplantation: an Italian study : NO024
Telemedical follow up visits after allogeneic stem cell transplant; working to improve patient care in northern Sweden : NO025
Peripherally inserted central catheter (PICC) in hematopoietic stem cell transplantation : NP001
NP002
Outdoor physical activity for hematological patients: does it improve quality of life? : NP003
The effect of reflexology for patients undergoing hematopoietic stem cell transplantation : NP004
Central venous catheter and peripheral venous access comparison at the allogeneic donors : NP005
Spectra Optia CMNC® is equivalent to Optia MNC® apheresis for T-cell collection and has the potential to offer greater harvest customisation : NP006
The emotional impact on adolescent sibling bone marrow donors : NP007
Treating patients suffering from grade IV acute graft vs host disease (aGvHD): ethical dilemmas and coping strategies on a curative-palliative spectrum : NP008
Autologous haematopoietic stem cell transplantation for multiple sclerosis managed with double lumen PICC's at Imperial college healthcare NHS trust: our experience : NP009
Experience of performing stem cell harvest on multiple sclerosis patients using cyclophosphamide and G-CSF mobilisation : NP010
Investigate and explore the cause of infusion-related adverse events of the third-part cord blood stem cell : NP011
Oral cryotherapy reduces the need of total parenteral nutrition and intravenous glutamine support for patients receiving myeloablative conditioning regimens : NP012
Ultrasound-guided peripheral vein cannulation reduces the need for central venous catheterization for peripheral blood stem cell harvest procedures : NP013
The CVC management handbook: integration of information for continuity care in a pediatric hematology unit/day hospital/hospital/territory : NP014
Importance of patient education prior to cyclophosphamide priming of multiple sclerosis patients : NP015
Improving the quality and consistency of patient education on discharge post autologous stem cell transplant : NP016
Think VOD: early detection—life-saving : NP017
A survey to examine the effects of a new electronic prescribing and notes system within a large stem cell transplant unit : NP018
Systemic sclerosis and cardiotoxicity in hematopoietic stem cell transplantation: a reported case : NP019
Implementing patient self administration of subcutaneous granulocyte-colony stimulating factor (G-CSF) : NP020
Developing the role of the inpatient advanced nurse practitioner : NP021
How do you define safe staffing levels on a blood and marrow transplant unit? : NP022
Innovative ways of delivering a triage service to provide haematology and renal patients direct access to specialist services : NP023
Risk factors for hematopoietic stem cell infusion related toxicity in children: the search for a safe procedure : NP024
An island of coexistence in the pediatric bone marrow transplantation unit: the role of the social worker : NP025
Comparison of levels of hope, hopelessness, depression, and the factors affecting them between the patients scheduled and those undergoing hematopoietic stem cell transplantation : NP026
Nausea and emesis management in patients undergoing allogeneic stem cell transplantation: a GITMO survey on 54 Italian transplant centers : NP027
Nutritional status and quality of life perceived by oncohematologic patients : NP028
Pilot study investigating sexual dysfunction in patients after allogeneic stem cell transplantation in Croatia : NP029
The Nurses' Group of GITMO was curious to know if Italian patients do have a chance to maintain their physical performance during hospitalisation for haematopoietic stem cell transplantation : NP030
Central line associated blood stream infection (CLABSI) zero target in adult BMT and hematology patient : NP031
Impact of early enteral nutrition in high dose chemotherapy with autologous stem cell support in children, adolescent and young adult with solid tumor or lymphoma : NP032
Imperial college healthcare NHS trust's apheresis unit experience of performing combined plasma exchange and erythrocytapheresis (RBCX) for treatment of multiple organ failure due to suspected fat embolism in sickle cell disease : NP033
Improving the compliance of biphosphonate therapy in patients with multiple myeloma : NP034
Knowledge and practices of haematology nurses in preventing central venous catheter related infection : NP035
Nursing management of peripherally inserted central catheter (PICC) and the incidence of PICC-related thrombosis in patients undergoing hematopoietic stem cell transplantation : NP036
Patients' experience undergoing a stem cell transplant as outpatients : NP037
Plasmapheresis as rescue therapy in immune thrombocytopenia (ITP) : NP038
Productive Ward implementation with focus on central venous catheter care : NP039
Reduction in malnutrition with enteral feeding: the efficiency of collaboration between a Hematology Intensive Care Unit (ICU) and a Transversal Nutrition Support Unit (TNSU) : NP040
Systemic Inflammatory Response Syndrome (SIRS) to needle on palatine: a reflection on antibiotic management when patients trigger SIRS : NP041
Implementing and improving the holistic needs assessment for autologous stem cell patients : NP042
Live births after hematopoietic stem cell transplantation : NP043
The impact of Anthony Nolan transplant specialist nurse for improving access to and the provision of late-effects services : NP044
Effect of three different solutions used in patients with hematological malignity on oral mucositis : NP045
Patient symptom assessment using the Edmonton Symptom Assessment Scale (ESAS) during autologous stem cell preparation, mobilization and after collection : NP046
A narrative-based medicine experience as a tool to assess the health care in hematopoietic stem cell transplantation : NP047
Assessment of body weight in children with hematological malignancy and non-malignant disorders after BMT and chemotherapy : NP048
Challenges in a tunneled central venous catheter care in Pediatric cancer ward : NP049
Exploring predictors of workplace violence and its effect on oncology nurses : NP050
Previously Published : NP051
Incidence of culture positive infectious episodes and outcomes after auto-SCT in lymphoma patients: a retrospective observational study : NP052
Oral mucositis during melphalan conditioning for autologous transplantation in multiple myeloma: can local cryotherapy help? : NP053
Patients with graft versus host disease after allogenic stem cell transplantation and their quality of life after eight treatment cycles with extracorporeal photopheresis : NP054
Pilot study into short synacthen tests on GvHD patients receiving ECP after stopping long term steroids : NP055
Quality indicators in the quality program for a clinical and apheresis unit : NP056
Reviewing the feasibility of chronic GvHD patients completing FACT BMT quality of life forms in photopheresis unit : NP057
A single-centre experience in the establishment of a pain management team : NP058
Successful nursing experience for extreme grade IV toxic epidermal necrolysis skin detached graft-versus-host disease—cases and techniques sharing : NP059
The interactive educational approach in management of anxiety related to bone marrow transplantation : NP060
Previously published : NP061
Treatment adherence: a challenge for patients receiving allogeneic transplant. A nursing intervention : NP062
Wiskott-Aldrich syndrome: a nursing care challenge : NP063
Austrian Stem Cell Transplantation Registry (ASCTR)—preparing for the future : P739
Blood and Marrow Transplantation Program experience at King Hussein Cancer Center : P740
Confounders of Consent: a Single-Centre Analysis of Predictors of Consent in a Stem Cell Transplant Service (SCT) : P741
Previously Published : P742
Regular feedback of data quality measures improves the reliability of outcomes analysis : P743
The Challenges in Achieving Accurate MEDA Reporting for Multiple Myeloma Autologous Recipients : P744
Adoptive immunity transfer from donor renders protective effect against hepatitis B reactivation after allogeneic transplantation for patients with resolved hepatitis B infection—A large endemic medical center report : P745
Comparing Bayesian Cox Regression Model to Classical COX Regression Model in predicting overall mortality of Acute Leukemia patients who underwent Allogeneic Stem Cell Transplantation (HSCT): 954 cases : P746
Previously published : P747
Previously published : P748
Modeling time-dependent effects for competing risks endpoints in allogenic stem cell transplantation—a piecewise constant approach : P749
The role of the Registry in assisting Transplant Centres to select and request Cord Blood Units for patients in need of Umbilical Cord Blood Transplantation : O180
Utility of routine evaluation of the sterility for cellular therapy product with or without extensive manipulations: best practices : O181
Implementing the validation process of the 6th edition of JACIE standards in the Clinical Unit and Bone Marrow Collection Facility : O182
Risk assessment of chemotherapy infusion process by using failure mode and effects analysis (FMEA) : O183
Defining competency to empower the Quality Professional in Healthcare : O184
Do we need to address cross-cultural issues in EBMT? : O185
Errors, accidents and adverse events reporting—a summary of nine years' experience in the JACIE accredited center : P750
Validation of the Sepax® 2S-100 (Biosafe®) using a Density Gradient Automated system for the Separation of Mononuclear cells (MNC) in ABO Mismatched Allogeneic Bone Marrow Tansplantation : P751
The market of cell therapies: a challenge for fair access : P752
How to build an Allogeneic Hematopoietic Cell Transplant Unit in 2016: proposal for a practical framework : P753
Infusion of Thawed HPC via a Volumetric Pump : P754
Comparison of different treatment options for MDS patients who relapsed after first allogeneic transplantation : O186
Methodology in relative survival : O187
Single vs. double auto vs. autol-allo in plasma cell leukemia : O188